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ABSTRACT
 
The purpose of this thesis for the degree of Master of Science was to use molecular and 
immunological techniques to study cellular responses to dengue virus infection.  In the initial study, 
Differential Display was used to compare mRNA expression in dengue-infected K562 cells and mock-
infected cells.  Cloning and sequencing were then used to identify cellular genes that were potentially 
up-regulated in response to Dengue virus infection.  These genes included bleomycin hydrolase and a 
dystrophin homologue. 
The goal of the later part of this research was to construct a recombinant vaccinia virus 
expressing the dengue 1 Hawaii NS3 protein.  Cytotoxic T-lymphocyte assays and protein gel 
electrophoresis showed that the NS3 protein was being expressed.  This construct was then used to 
study the cytotoxic T-cell response of a dengue 1 vaccine recipient.  The results of this study showed 
that this individual has dengue 1 NS3 specific T-cells and also that this vaccinia virus can be used for 
subsequent T-cell studies. 
 iii
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GENERAL BACKGROUND 
 
 
Dengue Virology 
 
 The Dengue virus is a member of the family Flaviviridae.  These viruses are single-stranded 
positive-sense RNA viruses.  Dengue viruses exist as four serotypes 1, 2, 3, and 4.  The genome encodes 
three structural proteins and seven non-structural proteins.  The structural proteins are the Capsid (C), 
Membrane (M), and the Envelope (E).  The non-structural proteins are designated as NS1, NS2a, NS2b, 
NS3, NS4a, NS4b, NS5.  The genome is approximately 10.7 kilobases and is translated into a single 350 
kDa polyprotein that is cleaved by host cell and viral encoded proteases (Fields et al., 1996).   
 
Dengue Diseases 
 
 Dengue viruses cause two syndromes:  Dengue Fever (DF) and Dengue Hemorrhagic 
Fever/Dengue Shock Syndrome (DHF)/(DSS).  Dengue Fever is a self-limited febrile disease, characterized 
by fever, muscle aches, bone pain and retro-orbital pain (Kurane and Ennis, 1992).  Other symptoms and 
signs include severe arthralgias, headache, accompanying maculopapular rash, leukopenia, and mild 
thrombocytopenia (Rothman, 1997).  These symptoms subside without complications within about a week.   
 In some patients, viral infection can cause plasma leakage into interstitial spaces.  As a result, 
patients suffer hypovolemia and sometimes circulatory collapse.  This syndrome is termed DHF because it 
is almost always accompanied by thrombocytopenia and hemorrhaging.  When plasma leakage becomes 
profound, shock can occur.  This is known as Dengue Shock Syndrome.  DHF was categorized into four 
grades, 1 through 4, by the World Health Organization, where 1 is the least serious and 4 is the most 
serious.  DHF grades 3 and 4 are called DSS (Technical Advisory Committee, 1980).  The pathogenesis of 
DHF/DSS is not fully understood.  Immediate medical treatment can abate the hypovolemia and usually 
prevent lasting organ dysfunction (Rothman, 1997).  This condition is often life threatening, especially for 
children between the ages of 3 and 14, as shown in Figure 1.   
 
 
 
 
 
 
 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 1: Age distribution and the occurrence of shock in DHF.   
     From Halstead et al., 1970. 
 
 
Dengue Hosts 
 
 The mosquito vector Aedes aegypti transmits the dengue virus (Halstead, 1981).  These 
mosquitoes transmit the virus to humans, and it is thought that the virus is perpetuated by the human-
mosquito-human transmission cycle.  Lower primates can be infected with dengue but do not develop 
clinical symptoms of DHF or DSS (Gubler, 1994).  The mosquito breeds in stagnant pools of water near 
human habitats, especially in warm climates such as in South America and Southeast Asia (Gubler, 1989).  
There have been many outbreaks in recent history, the most notable of which is the Cuban outbreak in 1981 
(Guzman et al., 1984).  This outbreak claimed 158 people, while 350,000 were estimated to be infected.  
Although almost every country in the Western Hemisphere has attempted to eradicate the mosquito, only 
Cuba succeeded after the 1981 outbreak using military force and pesticides.  The success was not 
permanent however, as Cuba experienced another dengue outbreak in 1997.  According to the government, 
838 people were infected but independent news agencies put the toll at 30,000.  The death toll ranged from 
3-20 (Taubes, 1997).  Recently, the numbers of this mosquito species have been increasing on the  North 
American continent, appearing in Florida, Texas, Alabama, and Mississippi.  This increase may promote 
the emergence of dengue diseases, thus posing a potential health threat in the continental United States.  
Figure 2 shows the geographical representation of regions affected or potentially affected by dengue 
infection.   
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Figure 2: Geographic Regions of Recent Dengue Activity.   From The Center for Disease Control 
Public Health Image Library. (http://phil.cdc.gov/Phil/default.asp) 
   
 
Animal Models 
 
 Because the virus has only been shown naturally to infect mosquitoes, humans, and lower 
primates, the development of an economical model has been problematic.  Baby mice that are challenged 
intracerebrally with dengue virus have been shown to produce subclinical infections, but symptoms are 
generally sporadic.  Adult mice generally produce no symptoms (Boonpucknavig et al., 1981).  Therefore, 
work has been done to create a disease model using SCID (Severe Combined ImmunoDeficiency) mice 
(Bosma et al., 1983).  SCID mice that were reconstituted with adult peripheral blood lymphocytes have 
been shown to support dengue type 1 infection, but the frequency of such infection is low (Wu et al., 1995).   
The infection frequency was shown to be improved with implantation of the human cell line K562 infected 
with dengue type 2 virus.  The K562-SCID mice do not show the clinical symptoms of DHF/DSS, but the 
fact that they have extra cerebral infection sites make them a more suitable animal model than cerebrally-
infected mice (Lin et al., 1998).  The lack of a proper animal model for DHF/DSS requires that we employ 
methods of epidemiology to study the disease in humans.  Consequently, the molecular aspects of dengue 
virus and infection are currently limited to in vitro models.   
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Recent Developments in Therapy and Prevention 
 
 Currently, methods of attacking the virus are being researched.  The development of antisense 
oligonucleotides that bind to the viral positive sense RNA genome to block its replication and translation in 
vitro, is one such advance.   However targeting the oligos to the cytoplasm, where the virus replicates, and 
not to the nucleus has been a hindrance in the further development of this treatment (Raviprakash et al., 
1995).  There has also been an attempt to infect A. aegypti mosquito with another virus carrying an 
antisense RNA to the dengue pre-membrane protein, which would block the replication of dengue in the 
mosquito salivary gland.  Although this approach may work in theory and in the laboratory, field 
applications are not yet feasible, and the effect of the carrier virus has not been tested in humans (Olsen et 
al., 1996).     A live attenuated tetravalent dengue vaccine has been in development for several years.  
Phase I clinical trials with the vaccines are currently underway (Jirakanjankit et al., 1999).   
 
Dengue Pathogenesis 
 
 The cascade of dengue pathology begins with the primary infection of the host.  Cytotoxic, helper 
and memory T-cells are activated and antibodies to the virus are secreted.  The T-cell population is both 
serotype specific and serotype cross-reactive due to the high homology between the serotypes.  Upon 
secondary infection by a different serotype, enhancing antibodies that are pre-existing from primary 
infection cause what is known and antibody dependent enhancement (ADE) of the viral infection.  
 ADE by dengue antibodies was first reported in 1977 by Halstead et al.  Their research 
demonstrated that human sera from dengue-infected patients enhanced dengue infection of peripheral blood 
mononuclear cells (PBMC) from non-immune patients.  ADE occurs when neutralizing antibodies at sub-
neutralizing concentrations, or non-neutralizing antibodies, bind dengue virus (Henchal et al. 1985).  IgG is 
the primary immunoglobulin associated with dengue ADE.  Antibodies to the Fcγ receptor (FcγR) of 
antigen-presenting cells block antibody dependent enhancement of dengue.  Thus, it has been elucidated 
that the dengue virus particle and the IgG antibody to the virus bind to create a virus-antibody complex.  
This complex binds to the FcγR via the Fc portion of the IgG, thus enhancing infection of the cell by 
bringing into closer proximity dengue particles with the putative heparan sulfate receptor or other receptors 
(Gollins and Porterfield, 1984; 1985). 
 Following cellular infection, serotype cross-reactive CD4+ and CD8+ memory T-cells are 
activated.  The CD4+ T-cells produce lymphokines such as IFNγ and IL-2 in response to activation, 
causing an upregulation of FcγR, MHC-I, and MHC-II production in new monocytes (Kelley et al, 1983).  
As a result of lymphokine production, it is thought that the complement cascade is activated, and in 
conjunction with the lymphokines, cause plasma leakage, hemorrhage, and shock. 
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Epidemiological observations have shown that there is a role for ADE in the pathogenesis of 
DHF/DSS.  It has been observed that, in Thailand, 99% of DHF/DSS afflicted children over the age of 1 
year  have antibodies to dengue virus before the infection causing DHF/DSS (Halstead 1988).  In patients 
under the age of one year, Kliks et al. (1988) have shown that there is a correlation between the age of 
infants who developed DHF/DSS upon primary infection the titer of existing antibodies in the sera of the 
mothers.  However, there have been rare cases of patients with DHF/DSS who did not have pre-existing 
antibodies to dengue and who showed a primary immune response.  These patients provided evidence that 
there may be other factors involved in the pathogenesis of DHF/DSS, including virulence of virus strains 
and host genetic factors (Scott et al. 1976). 
 
Purpose of Thesis  
 
 The purpose of this thesis is to investigate the cellular and immunological response to dengue 
infection.  The research in Part 1 was to prescreen for potential upregulation due to dengue infection.  
Differential Display was used to compare mRNA expression of Dengue-infected and mock-infected cells.  
Cloning and sequencing was used to identify genes that may be upregulated due to a stress response to 
infection.  The goal of Part 2 was to construct and use a recombinant vaccinia virus expressing a dengue 
protein to examine the T-cell repertoire of an experimental dengue vaccine recipient.
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BACKGROUND - PART 1 
 
This research was conducted in conjunction with Dr. Tammy Spain-Santana and Cynthia Drainville (’99 
WPI) 
 
K562 Cell Line and Dengue Type 2 
 
 The in vitro system that was chosen to study the effects of dengue infection on cellular gene 
expression is the human K562 immortalized cell line.  This line was isolated from a patient with chronic 
myelogenous leukemia and was first characterized as an erythroleukemic cell line.  However, a recent study 
has shown that the cells are “multipotential, hematopoietic malignant cells that spontaneously differentiate 
into recognizable progenitors of the erythrocyte, granulocyte and monocytic series” (Lozzio et al., 1981), 
and can therefore be characterized as a myelomonocytic cell line.  Primary monocytes can be cultured in 
vitro, but the isolation of monocytes alone is difficult and the isolation can cause non-specific activation.   
In addition, primary monocytes have a low infection rate in culture.  Other cell lines, such as U937 and 
THP-1, that have been used previously to model monocytes were found to not be suitable to the current 
study due to the fact that a high infection rate can only be achieved with pre-treatment to activate the cells 
(Spain-Santana, personal communication 1998).  This pre-treatment with activators would complicate the 
current study, which is investigating the immediate reaction of the cells to dengue infection.    
 The dengue strain that was chosen was a strain of dengue serotype 2 isolated in Sri Lanka.  
Dengue 2 strains have been shown to more frequently cause severe dengue infection in Cuban, Caribbean 
and South American dengue outbreaks (Rico-Hesse et al., 1997).  Secondary infection by serotype 2 has 
been shown to be a risk factor in the development of DHF/DSS (Sangkawibha et al., 1984). Also, dengue 
virus 2 strains (D2V) are the most efficient at infecting cells in vitro.  It is the serotype most commonly 
used in laboratory studies.  The Sri Lanka strain was found to be more infectious than the D2V New 
Guinea C strain in preliminary experiments (Spain-Santana, personal communication 1998).  
 
Differential Display and its Uses 
 
 Differential Display (DD) is a widely used method for identifying differentially expressed genes.  
Subtractive hybridization and microchip arrays are other technologies used for the same purpose. 
Differential display has several advantages over hybridization assays.  Hybridization assays often result in a 
loss of information about differential expression of highly homologous proteins within a gene family.   
Because DD is a non-hybridization technique, gene family differential expression can be detected.    The 
identity of differentially expressed genes can be verified via secondary methods (Martin et al., 1998).  
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Verification can be achieved using Northern Blot Analysis, but it requires time and can be very laborious 
when you have many genes.  Most importantly, Northern blotting is not sensitive enough to detect many 
genes detectable by Differential Display.  Martin et al. (1998) discuss strategies and techniques aimed at 
minimizing false positives and avoiding the use of impure Northern Blot probes that are generated from 
PCR-amplified DD bands.  This research at Dana Farber centered around breast cancer from which they 
have developed a new strategy for Differential Display in order to identify and verify gene expression 
among a large number of genes.  They identified the differentially expressed bands, excised, and eluted 
them.  The bands were directly sequenced and were queried against GenBank by BLAST.  They defined a 
match as “...≥ 96% identity of bases over a stretch of  ≥ 30 bases” (Martin et al., 1998).  A gene specific 
primer (20mer) was designed so that it would hybridize to the DD fragment with the arbitrary primer site.  
The primer was also used to PCR amplify a homologous probe for Northern Blot Analysis. 
 Their streamlined strategy (Figure 3) has enabled them to identify tumor suppresser genes rapidly 
with a negligible rate of false positives (Martin et al., 1998).  There were two approaches regarding 
sequence information.  If it was readable, it was used to design a gene specific primer.  Those that were 
poor were cloned and screened for differential expression.   
 
 
 
  Figure 3: Strategy for Identifying and verifying differential expression  
     of DD bands.  From Martin et al., 1998. 
 
 
Martin et al. (1998) consider direct sequencing as the first useful step in identifying and verifying DD 
bands versus hybridization assays because it only takes into account populations that are best represented.  
Hybridization assays focus on what binds the best-not population representation.   
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MATERIALS AND METHODS - PART 1 
 
 
Virus preparation and cell culture 
 
 Dengue type 2 virus Sri Lanka was cultured in C6/36 mosquito cells as previously described 
(Kurane et al., 1984).  The human cell line K562, a myelomonocytic cell line was grown in RPMI 1640 
medium supplemented with L-Glutamine, penicillin, streptomycin, and 10% fetal bovine serum (FBS).  
The cultures were maintained at 37°C.   
 
Infection of K562 cells 
 
 Twenty-four hours prior to infection, 107 cells were put into mid-log phase by adding 20% FBS 
RPMI and incubating for 24 hours at 37°C.  Cells in mid log phase were then washed twice with 2% FBS 
RPMI.  After removal of excess media, pellets were resuspended and D2V (MOI: 10) or a control of C6/36 
cell culture supernatant was added.  Virus-infected cells were designated KD and mock-infected cells were 
designated KC.  Virus was adsorbed to cells for 2-3 hours at 37°C with shaking.  Cells were then incubated 
in a total volume of 10 ml of 10% FBS RPMI and at 37°C for 24 hours.  Cells were harvested by washing 
with PBS and then resuspended in 1 ml of PBS.  10 microliters of this suspension was dotted onto a slide 
for indirect immunofluorescence Assay (IFA) (see below).  Cells were then resuspended in Buffer RLT 
plus ß-mercaptoethanol according to the Qiagen RNeasy Kit and were stored at -70°C.   
 
Indirect Immunofluorescence Assay (IFA) 
 
 Cells adhered to glass slides were fixed in EtOH at -20°C for 10 minutes.  Slides were stored at 
4°C until staining.  Fixed cells were incubated with anti-D2V hyper-immune ascitic fluid in a humidifying 
tray at 37°C for 30 minutes.  Slides were then washed with phosphate-buffered saline (PBS). Cells were 
incubated with fluorescein or rhodamine conjugated goat anti-mouse IgG at 37°C with humidity for 30 
minutes.  Cells were counted under a light microscope.  Dengue antigen positive cells were visualized 
under a UV light microscope.  Dengue antigen positive and negative cells were counted to determine the 
percentage of infected cells. 
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Total RNA extraction 
 
 The RNeasy Kit by Qiagen was used to prepare total RNA from D2V-infected cells and mock-
infected cells. RNA was quantified spectrophotometrically by measuring absorbance of UV light at 260 nm 
and using the following equation: OD (A260) x Dilution Factor x 40 ng/ul x total volume = total yield, 
where OD (A260) is the optical density of the sample at a 260 nm wavelength.  Total RNA was stored at -
70°C until ready for use. 
 
mRNA Isolation 
 
 Cellular mRNA was isolated from total RNA using the PolyATtract System mRNA isolation kit 
(Promega).  150 µg of total RNA was expected to yield approximately 5 µg mRNA.  Prepared mRNA was 
stored at -70°C until Northern Blotting. 
   
Differential Display (DD) 
 
            The Delta Differential Display kit (CLONTECH Laboratories, Inc.) was used to compare RNA 
from dengue-infected and mock-infected cells.  The Kit comes with 10 P primers of arbitrary sequence of 
25 nucleotides and 9 T primers of 30 nucleotides, which contain a poly-T anchor at the 3' end.  The P 
primers were designed to recognize common sequence motifs found in coding regions of eukaryotic 
(especially mammalian) mRNAs (Differential Display Protocol). We chose to perform PCR with 
combinations 1 of each of P and T primers, starting with T9 and P1-P10, and T8 and P1-P10.   Differential 
Display primer sequences are shown in Table 1.   
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Table 1: Differential Display Primer Sequences (CLONTECH Laboratories, Inc.) 
 
Name Length Sequence 
T8 30-mer CATTATGCTGAGTGATATCTTTTTTTTTGC 
T9 30-mer CATTATGCTGAGTGATATCTTTTTTTTTGG 
P1 25-mer ATTAACCCTCACTAAATGCTGGGGA 
P2 25-mer ATTAACCCTCACTAAATCGGTCATAG 
P3 25-mer ATTAACCCTCACTAAATGCTGGTGG 
P4 25-mer ATTAACCCTCACTAAATGCTGGTAG 
P5 25-mer ATTAACCCTCACTAAAGATCTGACTG 
P6 25-mer ATTAACCCTCACTAAATGCTGGGTG 
P7 25-mer ATTAACCCTCACTAAATGCTGTATG 
P8 25-mer ATTAACCCTCACTAAATGGAGCTGG 
P9 25-mer ATTAACCCTCACTAAATGTGGCAGG 
P10 25-mer ATTAACCCTCACTAAAGCACCGTCC 
 
 
 
             Total RNA from mock-infected cells and dengue-infected cells was used to synthesize cDNA per 
the Differential Display protocol.  PCR was performed in a Perkin-Elmer Thermal Cycler 480 with mock-
infected cDNA, cell-infected cDNA, positive control total RNA,water controls and the appropriate primer 
combinations. PCR cycles were as follows: 
1 Cycle: 
94°C 5 min 
40°C 5 min 
68°C 5 min  
2 Cycles: 
94°C 2 min 
40°C 5 min 
68°C 5 min 
25 Cycles: 
94°C 1min 
60°C 1min 
68°C 2 min  
68°C for 7 minutes 
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              PCR samples were analyzed on a 5% polyacrylamide/8M urea denaturing gel, prepared and run as 
directed. After the run, the gel was transferred to Whatman paper and dried on a gel dryer at 80°C for at 
least 30 minutes.  The DD PCR products were visualized by autoradiography.  Bands that appeared in the 
dengue-infected sample but not in the mock-infected sample were excised out of the differential display gel 
and eluted in 40 ul TE buffer by heating for 5 minutes at 100°C and then incubating the sample at 60°C 
overnight.  The eluted cDNA was re-amplified with PCR according to the Delta Differential Display Kit. 
PCR cycles were as follows: 
30 Cycles: 
94°C 1 min 
60°C 1min 
68°C 2 min 
 
             Prior to being sequenced, PCR products were desalted using a QIAquick PCR Purification Kit 
(QIAGEN). For the direct sequencing reactions, a 40:1 primer to template ratio was used.  The T primer 
that was used to generate each product was used for sequencing.  ABI dye-terminator sequencing was 
performed. Sequences were analyzed by the GCG program (Wisconsin package) and GenBank BLAST 
Search tool at the NCBI website. 
 
Cloning 
 
 cDNA eluted from a differentially expressed band of the differential display gel was isolated and 
ligated into the pCR2.1-TOPO vector using a TOPO TA Cloning Kit (Invitrogen). The plasmid was 
transfected into competent cells which were then plated on LB agar plus ampicillin (50 µg/ml) and x-gal 
for blue/white selection.  The plates were incubated 24 hours at 37°C.  Ten white colonies from each plate 
were picked and grown overnight in 2 ml Luria Broth with ampicillin (100 µg/ml). Plasmid DNA was 
prepared using QIAprep Spin Miniprep columns (Qiagen).  Plasmid DNA was digested with EcoRI to 
confirm the presence of an insert.  500 ng of PhiX174 DNA-Hae III Digest was used for a marker.  Gels 
were stained with ethidium bromide.  Plasmid DNA was sequenced with primers T7 and M13R.  
   
Northern Blot analysis 
 
 mRNA samples were separated by gel electrophoresis on a 2% agarose gel.  Using standard 
Northern Blotting protocols (Current Protocols in Molecular Biology), the mRNA was transferred to a 
nitrocellulose membrane.  The membrane was then dried and RNA cross-linked to the membrane under UV 
light for 3 minutes. Northern Blots were first probed with Actin or GAPDH (Ambion).  Probes for 
Northerns were generated from DD bands by PCR amplification of differentially expressed DD products 
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cloned into plasmids.  PCR of plasmid DNA was performed with the following specifications with primers 
from the original differential display: 
30 Cycles: 
94°C 1 min 
60°C 1min 
68°C 2 min 
 
 10 µl of the PCR reaction was then gel purified by the QIAquick Gel Extraction kit. The gel 
purified DNA (25 ng to 100 ng) was used as template for probe using the StripEZ StripAble probe 
synthesis (Ambion).  Unincorporated nucleotides were removed with MicroSpin G50 columns (Pharmacia 
Biotech). Specific Activity was measured using a scintillation counter.  Probe was hybridized to the blot in 
Hybridization solution (5X SSC, 1% SDS; 42°C rolling overnight) and the Northern was washed according 
to standard methods: 2X with 2X SSC/0.1% SDS, 5 minutes at room temperature, 2X with 0.2X SSC/0.1% 
SDS, 5 minutes at room temperature. The Northern was visualized and analyzed with a PhosphorImager.  
Northerns were stripped using Mild Stringency Strip Solution (5 mM Tris, pH 7.5, 2 uM EDTA, pH 8.0, 
0.1X Denhardt’s Solution) at 65°C for 2 hours and rinsed with 2X SSC, or using the StripEZ protocol for 
removal of StripAble Probe (with 1X Probe Degradation Buffer 68°C for 10 minutes followed by 1X Blot 
Reconstitution Buffer at 68°C for 10 minutes). 
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RESULTS - PART 1 
 
Purpose 
 
The purpose of Part 1 was identify potentially upregulated host genes of K562 cells infected with 
dengue virus 
 
Differential Display 
 
 Differential Display was used to compare gene expression levels in two populations: dengue-
infected K562 cells (KD) and mock-infected K562 cells (KC).  Eighteen primer combinations were used 
for the display.  Any bands that were present in the KD lanes but not in the KC lanes were excised and the 
DNA used for further analysis. From these gels, shown in Figure 4, bands 3, 6, 30, 64, and 57 (not shown) 
were isolated.   
 
A                                   B                           C                             D        
 
Figure 4: Differential Displays that identified bands 3, 6, 30, and 64.  (Band 57 is not 
shown).  Each display has four lanes: mock-infected (KC) 1:10 dilution, mock-infected 
1:40 dilution, infected (KD) 1:10 dilution, and infected 1:40 dilution.   Primers for each 
Differential Display reaction are as follows: Panel A: Band 3 P2+T9, Panel B: Band 6-
P2+T9, Panel C: Band 30-P1+T9, Panel D: Band 64-P6+T9. See Materials and Methods 
for primer sequences. 
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Band Cloning 
 
Once these bands had been identified as potentially upregulated mRNAs, PCR reamplification was 
performed on the isolated cDNA in order to determine fragment size, as shown in Figure 5.  A Phi X 
174/Hae III digest Marker was used.  Table 2 summarizes the sizes of these bands of interest, which are 
band 3 at 240 base pairs, band 6 at 800 base pairs, band 30 at 200 base pairs, band 57 at 110 base pairs and 
band 64 at 450 base pairs.   The reamplification products were then cloned into plasmid TOPO TA pCR2.1 
and transformed into E. coli.  Plasmid DNA was prepared from as many as 10 colonies per band.  
Restriction digests of the plasmids with EcoRI was performed to confirm size and presence of insert (Data 
not shown).   Figure 5a shows the size of the insert of each clone of interest.  The figure shows that each 
clone has as insert of the size of the original DD product. 
Table 2: Sizes of DD Bands 
 
 
DD Band Size 
3 240 bp 
6 800 bp 
30 200 bp 
57 110 bp 
64  450 bp 
 
 
 
Figure 5: PCR Reamplification of bands 3, 6, 57, and 64 (30 not shown).  PCR reactions were 
performed with original DD primers for each band, run on 2% agarose gels and stained with 
ethidium bromide. 
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Figure 5a: PCR Reamplification of clone inserts by PCR 
 
Attempted Confirmation of Upregulation by Northern Blot Analysis 
 
The confirmation of differential expression was attempted initially for bands 30 and 57 using 
Northerns.  cDNA from clones 30B, 30E, 30H, 57B, 57F, 57G, 57H and 57J2 was used to generate 
radioactively-labeled DNA probes for Northern Blot analysis.  Messenger RNA from mock-infected and 
dengue-infected K562 cells was isolated and separated on a denaturing agarose gel, and transferred to a 
nitrocellulose membrane.  Data from two experiments with probes 30H and 57B can be found in Figures 6 
and 7.  After quantitative analysis of detected bands and standardization to Actin or GAPDH, confirmation 
of up-regulation of 30H and 57B could not be replicated.  For example, in the first experiment using a 
probe for 30H, a value of 1.7 was calculated for the standardized ratio of dengue-infected to mock-infected 
signals.  This would indicate that the mRNA that this probe is binding to is upregulated.  However, upon a 
repeat experiment with the same probe, a value of 0.5 was calculated indicating that the mRNA is down-
regulated.  The results were similar with probe 57B.  This could be due to technical errors including 
problems with probe preparation or varying amounts of RNA on the blots. 
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PhosphorImager Volumes and calculations 
 
Figure 6: Northern Blot Calculations of the Standardized Ratios for each experiment. 
 
 
Figure 7: Standardized Quantification of 
Northern Signals for Probes 30H and 57B.   
 
 
 
 
 
 
 
 
 
Band Identification by Sequencing 
 
In spite of Northern verification analyses producing ambiguous results, clones for bands 3, 6, 30, 
57, 63 and 64 that contained the correct size insert were sequenced.  Analyses of the sequences were 
accomplished with GCG programs and were then queried in GenBank.  The BLAST queries generated 
several possible gene candidates for the identities of several clones, which are summarized in Table 3.  
Only nonviral host genes that had some possible correlation with dengue infection or pathogenesis were 
chosen for further investigation.  These genes are human bleomycin hydrolase (clones 6D/6I) and human 
dystrophin gene (clone 3C), Human activin (clone 3A), human topoisomerase II (clone 64I), and human D9 
splice variant B (clone 6J).  The sequence alignments as generated by BLAST have been previoulsy 
reported (Brown and Drainville, 1999) 
Blot Probe Actin KC Actin KD probe KC probe KD sKC sKD sKD/sKC
A93-2 30H 13192 6799 16230 14225 1.23 2.1 1.700589
A94-3 30H 4938 4880 20108 10877 4.07 2.2 0.547358
A93-3 57B 12031 3711 39068 13902 3.25 3.7 1.153631
A94-4 57B 5554 3851 227752 83342 41 22 0.527757
Calculations: 
Probe KC/Actin KC = sKC
Probe KD/Actin KD = sKD
sKD/sKC = Standardized Ratio
0
0.5
1
1.5
2
sK
D
/s
K
C
 
Standardized Quantification of 
Northern Signals for 30H and 
57B
Standard
30H
30H
Standard
57B
57B
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Table 3: List of Candidate Genes 
 
Clone  Known Genes     BLAST Score 
6D/6I   H. Sapiens Bleomycin hydrolase   561/428  
3C  Human Dystrophin gene    42 
64I  Human DNA topoisomerase II   577 
3A  Activin beta C chain    184 
6J  Human D9 splice variant B     841 
30H  AMLI EAP translocation break point   200 
30H   H. sapiens Acute myeloid leukemia associated   200 
30H  Human mRNA for EBV small RNAs    200 
57B  Human Ribosomal protein S25   121 
 
Unknown Genes 
30E  Human DNA seq f1 PAC 265J14   186 
57D  Hu DNA seq PAC 370M22 on chr 22q12-qter.  133 
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DISCUSSION - PART 1 
 
 The purpose of this study was to identify potentially upregulated cellular genes in K562 monocyte 
cells following dengue infection.  This study is unique in that in the field of dengue research, little has been 
determined about the immediate cellular response to infection during the inflammatory response.  T-cell 
responses are clearly important to the pathogenesis of dengue infections but immediate monocytic reactions 
involved in sending cellular signals to aid in viral clearance, could be involved in viral replication or 
disease pathogenesis.  
 Our observations during this study allow us to draw some general conclusions about the K562 
infection system as a whole.  First, we have noted that the dengue virus is not an obtrusive virus.  K562 
cells do not undergo morphological changes when infected with the virus. Differential Display reflects this 
notion.  Over the span of this study, Spain-Santana calculated that only about 1.6% of cellular genes were 
affected by viral infection (personal communication, 1998).  An unusual aspect of this is that most of the 
genes affected seem to be upregulated rather than down regulated.  Generally, when a virus infects a cell, it 
is assumed that the virus shuts down cellular genes to concentrate on the replication, transcription, and 
translation of its own genes (Fields et al., 1994).  However, dengue seems to cause the cell to activate many 
cellular genes that are not otherwise activated.   
 Differential Display was used to perform a genome-wide screen for candidate genes that may be 
upregulated in K562 cells after dengue type 2 infection.  The Differential Display gels were run in triplicate 
using the same cDNA samples, and the identified bands of interest were later cloned.  DD is a PCR-based 
method which is not quantitative.  To avoid false positives, bands that appeared in the KD lane and not in 
the KC lane were chosen for analysis because they may indicate a significant level of transcription in 
infected cells that is lacking in mock-infected cells.  Clones were sequenced and then queried by BLAST to 
identify candidate genes.   These clones include the following:  6D/6I, 6J, 64I, 3A, and 3C.  A BLAST 
score of close to 200 bits or better (with the exception of 3C) was seen with each of these clones thereby 
meeting our criterion for probable gene identity.  Our general goal was to identify host genes that appear to 
be upregulated but which were not known to be involved in the immunopathology of dengue infection. 
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 Clones 6D/6I were identified as Bleomycin Hydrolase (Accession X92106).   Clone 6I (score 428) 
showed 97% homology to the human BH gene in 231 out of 236 bases, spanning the region 879-1114.  The 
homologous region was in the coding region of the BH gene.   The fact that 2 clones out of 10 shared 
homology (94%) to each other and were each separately identified as BH is significant.  Each DD band 
contains many same-sized messages and is it not immediately clear if there is one or more genes 
represented in the band that is upregulated.  The fact that the clones were essentially identical indicates that 
the message is abundant in the band and could most probably be a gene that is upregulated.  Bleomycin 
Hydrolase (BH) is a cysteine protease whose primary amino acid sequence was first deduced through the 
use of a rabbit liver cDNA library (Koldamova et al., 1998).  According to sequence analysis, the human 
BH lacks a signal sequence.  This suggests that it has a cytosolic/nuclear location (Bromme et al., 1996).  
Ferrando et al. (1997) performed further analysis of the 5' flanking region and found that the human BH 
gene did not contain consensus transcriptional sequences such as the TATA or CCAAT box.  This is 
consistent with the belief that the absence of such elements signifies a house keeping gene, thereby 
supporting its widespread expression within human tissue.  Additional analysis of the 5' flanking region 
identified an AP-1 consensus site (TGACTCA) upstream from the translation initiation site (Ferrando et 
al.,1997).  AP-1 is recognized by members of several families of transcription factors:  c-Fos, c-Jun and 
ATF-1.  AP-1 has also “...been found to mediate induction of different genes by a variety of tumor 
promoters, cytokines, and growth factors” (Angel et al., 1991).  It is not clear as to the types of pathological 
implications that the AP-1 sequence match may have, however, it may affect the role of the BH gene 
(Ferrando et al., 1997).   
 Bleomycin is an anti-cancer drug that was isolated from Streptomyces verticillus.  It is part of a 
family of DNA cleaving glycoproteins that is widely used in the treatment of human cancers.  The 
therapeutic efficacy of Bleomycin, unfortunately, is limited by tumor resistance and the development of 
pulmonary fibrosis (Koldamova et al., 1998). Bleomycin Hydrolase inactivates the anti-tumor glycopeptide 
bleomycin, which is one possible mechanism as to why there is tumor resistance (Bromme, 1996; 
Koldamova, 1998). It is plausible that the cellular upregulation of bleomycin hydrolase is a response to the 
stress of dengue infection by an unknown mechanism. 
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 Clone 64I was identified as DNA Topoisomerase II (Accession J04088).  Clone 64I (score 577) 
showed a 99% homology to the human Topoisomerase II gene in 294 out of 295 bases, spanning the region 
3153-3447.  This homologous region was the coding region of the top2 gene.  The top2 gene is essential for 
eukaryotic cell survival, and is also fundamental in cell growth development (Larsen et al.,1996; Sng et 
al.,1999).  Topoisomerase II is a component of the nuclear matrix and an enzyme that is required for DNA 
metabolism:  chromosome segregation and condensation, replication, and transcription (Larsen, et al.,1996; 
Matsuo et al., 1993; Nitiss, 1998; Sng, et al.,1999).  There are also two DNA transport cycles that it 
catalyzes:  DNA breakage/religation and ATP hydrolysis (Matsuo et al., 1993; Morris et al., 1999).  
Topoisomerase exists as two isoforms α and β that express different cell cycle and tissue expression 
patterns.  In proliferating cells, the α isoform is upregulated (Sng et al., 1999).  Heck et al. (1986) considers 
topoisomerase to be “...a sensitive and specific marker for proliferating cells.”    
 It is possible that the toposisomerase II gene is heat shock inducible (Matsuo et al., 1993) and is a 
target for several important anti-cancer agents.  The implications in anti-cancer drug resistance include the 
rearrangement and altered expression of these genes (Sng et al.,1999).  When cells become stressed either 
from physical (e.g. heat) or chemical (e.g. low pH) stressors, heat shock genes become induced and cause 
the release of Heat Shock Proteins (HSPs) (Macario, 1995).  HSPs possess an intrinsic capacity to protect 
cells during harsh environmental conditions and in combat against pathogens (De Maio, 1999).  According 
to Voellmy (1994), there is recent data that suggests a possible connection between cellular control 
mechanisms and stress response.  Multhoff et al. (1998) believe that “HSPs act as immunological target 
structures either by themselves because of an unusual expression pattern, or they are carrier proteins for 
immunogenic peptides.”   Non-MHC restricted effector cells such as natural killer cells and γ/δ TcR 
positive T lymphocytes have been shown to be major contributors in recognizing HSP.  According to 
Moseley (1998), there is data that further supports the role of HSPs in enhancing antigen presentation to T 
lymphocytes.   Although it is not clear as to how Topoisomerase II may be induced as a heat-shock-
inducible gene as a result of dengue infection, there may be some possible connection between dengue 
infection and an elicited T-cell response due to the HSPs that are released.  
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 Both Bleomycin Hydrolase and Topoisomerase II may have some implication involving anti-
cancer research, however, there is currently no evidence shown by anyone that there is a correlation 
between the dengue infection and cancer. 
 Clone 6J was identified as Human D9 Splice Variant B (Accession U95007).  Clone 6J (scores 
841, 161) showed homology within two regions.  The first region showed a  95% identity to the human D9 
Splice Variant gene in 544 out of 572 bases, spanning the region 91-659.  The second region showed a 96% 
identity to the gene in 88 out of 91 bases, spanning the region 1-91.  These homologous regions are part of 
the coding and 3’ UTR regions of the D9 gene.  The function of the D9 gene has not been characterized to a 
great extent.  There is some indication, however, that it may be involved in hematopoietic suppression 
(Scott et al., 1996).  This could be potentially interesting in light of recent data indicating that dengue 
infection of cord blood mononuclear cells inhibits hematopoietic progenitor growth.  The chemokine MIP-
1α (Macrophage inflammatory protein) is implicated in this suppression (Margue et al., 1998).  Dengue 
infection is often associated with hypocellular bone marrow and leukocytopenia, which could be 
indications of bone marrow suppression. 
 Clone 3A was identified as Activin beta-C chain (Accesssion X82540).  Clone 3A (scores 
184,149) also showed homology in two regions.  The first region showed a 100% identity to the Activin 
gene in 93 out of 93 bases, spanning the region 2112-2204.  The second region showed a 100% identity to 
the gene in 75 out of 75 bases, spanning the region 2014-2088.  These homologous regions are found in the 
3’ untranslated region of the Activin gene, a region with possible regulatory roles (Tanimoto et al., 1993).  
Activin, along with inhibin and follistatin (FS) are proteins that are well characterized in their ability to 
regulate follicle-stimulating hormone (FSH).  Activin, a member of the transforming growth factor B 
superfamily, acts through binding of its Type I and Type II serine/threonine kinase receptors for signal 
transduction.  Activin subunits and their receptors are widely expressed in a variety of fetal and adult 
tissues. 
 FS is known to be an activin-binding protein and was also shown to bind cell-surface heparan 
sulfate (HS) proteoglycans (Nakamura et al., 1991).  A proposed role for FS-activin binding was to 
inactivate the signal transducing capability of activin, as shown by Hashimoto et al. (1997), in rat pituitary 
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cells.  Another study had hypothesized that the FS-activin complex, which binds HS, facilitates activin-
receptor binding through local cell-surface interactions.  In either case, FS and/or HS seem to aid in the 
regulation of activin activity (Nakamura et al., 1991).   
 Heparan sulfate is a putative cellular receptor for dengue virus (Chen et al., 1997) (Note that HS 
has not been described on monocyte cell membranes, but that doesn’t preclude the possibility of it being 
present).  One possible explanation for the role of activin may be to increase the viral accumulation on the 
surface of monocytes or other infected cells.  Infected cells could secrete an increased level of activin, 
which could then bind FS and subsequently HS on other cells.  This complex might initiate a 
conformational change that allows dengue viral particles to bind HS.  HS could, as has been previous 
proposed, be a receptor or could simply aid in bringing the virus into closer proximity with the cell surface.  
The major problem with this hypothesis is that monocytic cell lines  monocytes (U937, K562 and others) 
are not known to express or secrete follistatin, and thus it is not known how this intermediate would be 
present.  Alternatively, activin may be acting as a signal-transducing molecule by binding its receptors 
(monocytes do express activin receptors).  However, the nature of the signal, perhaps to increase 
proliferation of monocytes or other cells, is unclear.  
 Clone 3C was identified as Human Dystrophin (Accession U60822).  Clone 3C (scores 42,36) 
showed homology in two regions.  The first region showed a 89% alignment to the Dystrophin gene in 33 
out of 37 bases, spanning the region 81417-81452.  The second region showed a 85% alignment to the gene 
in 36 out of 42 bases, spanning the region 81514-81555.  These homologous regions are found in a MER 
repeat region.  Although the evidence that this gene is actually upregulated is not convincing, the role that 
this gene may play in dengue infection could be potentially interesting and deserves further investigation. 
 Our study identified the dystrophin gene as a candidate for up-regulation in monocytes as a result 
of dengue infection.  Although dystrophin has never been shown to be expressed in monocytes, there exists 
the possibility that we have identified a dystrophin homologue.  There are several possible explanations for 
the up-regulation of a dystrophin-like molecule.  First, it has been shown that the α-dystroglycan (DG) unit 
of the Dystrophin-Associated Protein Complex (DAPC) is a receptor for the arenaviruses Lymphocytic 
choriomeningitis virus (LCMV) and Lassa Fever virus (Cao et al., 1998).  The α-DG unit is an extra-
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cellular membrane protein that binds to the extra-cellular matrix.  The Cao study indicates that the extreme 
N-terminus of the α-subunit, with possible post-translational modifications, is necessary for virus binding.  
Arenaviruses share several characteristics with flaviviruses, including a single-stranded positive sense RNA 
genome and as association with hemorrhagic fever (Fields et al., 1994).  There is then the possibility that 
dengue virus uses this subunit as a cellular receptor.  A putative cellular receptor heparan sulfate (HS) has 
been described for dengue virus type 2 (Chen et al., 1997), but this does not preclude the possibility of 
multiple receptors.   
 An alternative explanation for the upregulation of a dystrophin protein is rather more complex.  
Dystrophin, in skeletal muscle and neurons especially, binds the molecule Nitric Oxide Synthase (NOS) to 
the cytoskeleton.  NOS synthesizes Nitric Oxide (NO), which is a well-characterized free radical that acts 
as a neurotransmitter and also functions in smooth muscle relaxation (Bredt, 1996).  However, NO is 
integral in the understanding of several antiviral mechanisms.  NO has been shown to have an antiviral 
effect on the flavivirus Japanese Encephalitis virus (JEV) (Lin et al., 1997).  Monocytes have what has 
been termed inducible NOS (iNOS) that is activated in response to high levels of Interferon-γ (Ding et al., 
1988).  Lin et al showed that NO synthesized by iNOS inhibits the replication of the viral RNA genome, 
accumulation of viral proteins and virus release (1997).  NO production has also been implicated in the 
inflammatory response after resuscitated hemorrhagic shock, causing permanent organ damage (Hierholzer 
et al., 1998).  The similarities to dengue infection, which includes elevated IFN-gamma levels and liver 
involvement, indicate that the NO antiviral mechanism could be playing a role in dengue pathogenesis.   
 Thus we hypothesize that upon dengue infection, a dystrophin-like protein could be essential to 
aid in the cascade of cellular signals to initiate a NO antiviral response.  The diffusion of NO could play a 
role in dengue fever and shock and liver damage.  Due to the complexity of viruses, it is not an 
impossibility that the virus could be taking advantage of the cell's innate defense mechanism, and thus 
using the dystrophin molecule as a receptor to multiply-infect monocytes or to amass viral particles. 
 Preliminary experiments using Northern Blot Analyses were inconclusive in confirming the 
upregulation of the genes studied.  The results of repeated experiments did not agree.  This could be due to 
several reasons.  One reason could be suboptimal probe preparation; leaving unlabeled (cold) strands of  
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our cDNA.  This would compete with labeled probe and provide inaccurate results.  Another possibility is 
that the message that we were probing for was rare.  It is conceivable that this rarity in RNA can be 
represented unequally between Northerns, thereby creating conflicting results.   
 The clones sequenced above represent candidate genes that need further confirmation of their 
upregulation.  Techniques such as Northern Analysis, RNase Protection Assays, Reverse Northern Dot 
Blots or DNA microchip arrays could be used to verify the upregulation of these candidate genes.   
 Because this study was a genome-wide search for differentially expressed genes, there are literally 
limitless types of experiments that that could be performed.  Most importantly, the upregulation  of the 
genes (especially of Bleomycin Hydrolase) that we have identified needs to be confirmed.  This could be 
accomplished by using one or more of the techniques listed above.  Once this has been done, assays such as 
ELISAs could be performed to confirm the translational upregulation of the gene and aid in the elucidation 
of the gene’s potential role in immunopathology.  The Delta Differential Display kit that was used in this 
study contained 9 T primers and 10 P primers.  With a possible 90 PT combinations available, the primers 
could be used separately or used in several other pair combinations to offer a wide range of experimental 
opportunities to identify respective genes through Differential Display.   Furthermore, our study used 
mRNA from the time point of 24 hours post infection.  It would be opportune to perform time course 
differential displays or at other times post infection to compare banding patterns. 
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BACKGROUND - PART 2 
 
 
The Dengue NS3 Protein: Structure and Functions 
 
 The dengue protein NS3 may be one of the most important proteins for viral pathology.  Studies of 
the CD4+ and CD8+ cytotoxic T-lymphocyte (CTL) responses in patients immunized with candidate live 
monovalent dengue vaccines have shown that the NS3 protein is the most antigenic viral protein (Gagnon 
et al. 1996; Mathew et al. 1996).  Many serotype-cross-reactive and serotype-specific epitopes on NS3 
have been identified, which is contrary to the belief that most immundominant viral proteins contain 1 or 2 
T-cell epitopes.  A more complete understanding of the functions of the NS3 protein in viral replication, 
protein cleavage, and immune response is highly warranted, especially as a target for future treatment and 
prevention of dengue diseases. 
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 The serine protease domain of NS3 has been analyzed by x-ray diffraction by Murthy, Clum, and 
Padmanabhan (1999).  They have shown that the molecule contains 2 alpha helices and 5 beta pleated 
sheets, as shown in Figure 8 (PDB ID 1BEF, 1999).  This domain encompasses the N terminal 181 residues 
of the 618 amino-acid NS3 protein.  An alignment of the first 180 amino acids from the NS3 proteins from 
dengue virus types 1-4, (not shown) shows that the catalytic triad (His-51 Asp-75 Ser-135) is completely 
conserved in all four types. 
The remaining amino acids at the C terminal end of the NS3 protein have been characterized as 
having both NTPase and helicase activities.  This region contains motifs associated with these two 
proposed functions, including the DEXH family and the putative DEAH helicase family (Fu et al. 1998).  
The helicase and NTPase activities may function in viral replication.  The NTPase activity, specifically of 
ATP, may serve to provide free energy required for RNA binding, unwinding, and removal of secondary 
structures during negative–strand synthesis (Arai and Kornberg 1981; Deng and Shuman 1996; Hagler, Luo 
and Shuman 1994).  In support of these proposed functions, Fu et al. (1998) have shown that the NS3 
protein can complex with RNA at the 3’ non-coding region, and that the NS5 protein stimulates ATPase 
activity. They speculate that the NS5 protein may catalyze negative-strand synthesis during viral RNA 
replication. 
 
 
Figure 8: Serine Protease Domain of the NS3 Protein (Murthy, Clum, and Padmanabhan, 1999) 
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Summary of previously identified NS3 T-cell Epitopes  
 
Several studies between 1995 and 1998 have uncovered approximately nine regions of the dengue 
NS3 protein that contain epitopes that stimulate T-cell clones from dengue-immune patients.  A summary 
of the epitopes can be found in Table 4. 
Region 1 was discovered by Kurane et al. (1995).  Clones JK4 and JK43 were isolated from a 
D3V immune donor and were both cross-reactive for all four serotypes.  The epitope recognized by these 
clones is a 9 aa epitope between 146 and 154 of the D3V NS3 protein.  The last 7 amino acids of this 
epitope are completely conserved between all 4 types while the first and second positions vary.  Dengue 2, 
3, and 4 have a valine at amino acid 146 while dengue type 1 has an isoleucine.  Conversely, Dengue 1, 2, 
and 3 have a valine at amino acid 147, while Dengue 4 has an isoleucine.   
 Region 3 was identified by Mathew et al. (1998) using CTL clones established from PBMC of a 
Thai child recovering from natural secondary infection.  The clones from patient KPP94-024 were serotype 
2, 3 and 4 cross-reactive, but dengue 1 NS3 was not tested due to a lack of a vaccinia virus construct.  The 
epitope was mapped to amino acids 221-235 of the NS3 protein, which is identical in serotypes 2, 3, and 4.  
It is interesting to note that the epitope on Dengue type 1 NS3 differs by two amino acids: a serine for an 
aspartic acid at position 9 and a glutamic acid for aspartic acid at position 12.  One could hypothesize that 
the clones isolated in this study may not be Dengue type 1 NS3 cross-reactive due to the two amino acid 
substitutions.  
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Table 4:  Summary of Previously Identified Dengue NS3 T-cell Epitopes 
 
Source Cell Line Region CD4/CD8 A.A. of 
gene 
Epitope 
Kurane 1995 JK4,JK43 1 CD4+ 146-154 VIGLYGNGV 
Zeng 1996 JK44 2 CD4+ 202-211 RKYLPAIVRE 
Mathew 1998 KPP94-024 3C2 3 CD8+ 221-235 LAPTRVVAAEMEEAL 
Zeng 1996 JK15 4 CD4+ 241-249 IRYQTTATK 
Okamoto 1998 JK10,JK34,JK39,JK28,JK26 5 CD4+ 255-264 EIVDLMCHAT 
Okamoto 1998 JK49 5 CD4+ 257-266 VDLMCHATF 
Zeng 1996 JK13, JK5 6 CD4+ 351-361 WITDFVGKTVW 
Livingston 1995 CB6.17, CB 2.8 7 CD8+ 500-508 TPEGIIPTL 
Zivny et al., 1999   CD8+ 235-243 AMKGLPIRY 
Zivny et al., 1999   CD8+ 71-79  
 
Okamoto et al. (1998) identified Region 5 using clones from a D3V immune donor.  All clones 
were cross-reactive for all four serotypes, which can be supported by the observation that this region is 
completely conserved in all four serotypes. Two overlapping epitopes between amino acid 255 and 266 of 
the NS3 D3V protein were defined in this study.  Clones JK10, JK26, JK28, JK34, and JK 39 recognized 
the 10 amino acid sequence between amino acids 255 and 264 while JK 49 recognized the epitope between 
257 and 266. 
 Region 7 was identified in a study of CD8+ HLA-B35 restricted T-cell clones.  The donor from 
both Mathew et al. (1996) and Livingston et al. (1995) was immunized with dengue type 4.  Mathew et al. 
identified T-cells that were cross-reactive for D2V, D3V, and D4V.  Livingston et al. identified clone 
CB6.17 which is D4V serotype specific, and clone CB2.8 which is cross-reactive for D2V and D4V 
(subcomplex specific).  The smallest core epitope was determined to be amino acids 500-508 of the D4V 
NS3 protein.  This region of NS3 is rather well conserved between the four serotypes.  Serotypes 1 and 3 
are identical at this epitope, while 2 and 4 differ at position 8, substituting a serine or a threonine, 
respectively.  Serotype 2 also has a methionine at position 9, which is a lysine in the other three serotypes.  
 
HLA Restriction of T-cell Epitopes 
 
 Antigen presentation to T-cells is accomplished by a complex known as the Human Leukocyte 
Antigen (HLA).  The genetic composition of the complex encodes three loci for Class II HLA molecules 
and 7 loci for Class I HLA molecules.  Class I and II molecules are similar in that they are both 
glycoproteins and are involved in antigen presentation.  Class I HLA present antigen to CD8+  T-cells and 
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are expressed on almost all cells of the human body, with the exception of red blood cells.  HLA I 
molecules predominantly present antigens processed from bacteria or viruses that replicate within the 
cytosol of a cell.  HLA II predominantly present antigens from invaders that replicate outside of the cell or 
within cellular vesicles.  CD4+ cells are the recipients of antigen presentation by HLA II molecules.   HLA 
Class II molecules are expressed predominantly on macrophages and other professional antigen-presenting 
cells.  
 The human genome contains two copies of each allele for each locus of the HLA complex.  The 
genes involved with HLA class 1 molecules are B, C, E, A, H,G, and F.  The genes encoding HLA class 2 
molecules are DPB, DPA, DQB, DQA, DRB, and DRA.   The one allele through which an epitope of an 
antigen is recognized is termed the HLA restriction of that epitope.  This allele is necessary (but not 
sufficient) to have T-cell recognition of the epitope. 
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MATERIALS AND METHODS – PART 2 
 
Cell lines and Viruses 
 
Donor FS was immunized with an experimental live-attenuated dengue virus type 1 vaccine.  
Peripheral blood specimens were obtained from the donor 4 months after vaccination  (Green et al., 1993).  
Cells were cryopreserved for further use.  Dengue virus type 1 Hawaii was provided by Walter E. Brandt, 
Walter Reed Army Institute of Research.  The recombinant vaccinia virus expressing D3V NS3 protein was 
provided by Dr. M. Brinton, Georgia State University, Atlanta, GA.  The recombinant virus expressing 
D4V NS3 protein was provided by Dr. C. J. Lai, National Institutes of Health, Bethesda, MD.  CV-1  
(ATCC CCL 70) are African Green monkey kidney cells used for virus propagation.  Human Tk- cell line 
143B (ATCC CRL 8303) is an osteocarcinoma cell line used for the selection of recombinant vaccinia 
virus.  Various T-cell clones, BLCL and PBMC were provided by Dr. Francis Ennis, UMass Medical 
Center, Worcester, MA.  
 
CDNA Synthesis  
 
RNA from Dengue 1 Hawaii virus in C6/36 cell supernatant was prepared using the QIAamp Viral 
RNA preparation kit, and stored at –20˚C.  cDNA synthesis was performed for 10 µl of viral RNA with 
AMV-RT enzyme and 1 µl  (0.1 U/µl) random primer in a 50 µl reaction volume. The reaction was 
incubated at 72˚C for 2 minutes, and 42˚C for 5 minutes.  The following were then added to the reaction 
tube: 20 µ l 5X Reaction Buffer, 20 µl 2.5mM dNTP, 2.5 µl (40 U/µl) Rnasin and 3ul (10 U/µl) AMV-RT.  
The reaction was further incubated at 42˚C for 1 hour and then at 95˚C for 10 minutes.  The resulting 
cDNA was stored at -20˚C.   
 
PCR 
 
PCR amplification of the D1V NS3 gene and truncated gene fragments was carried out using the XL 
GeneAmp kit from Perkin Elmer.  Primer sequences are shown in Table 5.   
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Table 5: Sequence of PCR Primers 
 
Primer Name Length Direction Sequence Restricti
on site 
D1VNS35’ATG 32 nt Sense TTGTCGACATGTCTGGAGTGTTATGGGACACA Sal1 
D1VNS33’-2 29 nt Antisense TTGGATCCTCTTCTTCCTGCTGCAAACTC BamHI 
D1V1116 33 nt Sense TTTGTCGACATGGTGAAGAGTGAACACACAGG
A 
SalI 
D1V884-H3 33 nt Antisense TTTAAGCTTTAATATGCTGGCTGGATCGGTAAA HindIII 
 
The primer pair D1VNS35’ATG/D1VNS33’-2 amplifies the 1.8 kb NS3 gene, with flanking Sal1 and 
BamHI sites (underlined in the sequences above). The primer pair D1VNS35’ATG/D1V884-H3 amplifies 
the first 885 nucleotides of the NS3 gene (designated "884").  The primer pair D1V1116/D1VNS3’-2 
amplifies the last 1111 nucleotides of the NS3 gene (designated "1116").  There is a 144-nucleotide overlap 
of the PCR products of these two primer sets.  The sense primer was also designed to contain an ATG 
(shown in bold in the sequence above) that will enable consequent translation in the Vaccinia Virus to 
begin properly and in frame for NS3 protein synthesis.  The PCR conditions are shown in Table 6.  
 
Table 6: PCR Cycles 
 
Temperature Time Cycles 
94◦C 1 minute 1 
94◦C 30 seconds 
56◦C 1minute 
72◦C 5 minutes 
35X 
72◦C 10 minutes 1 
4◦C End  
 
 
PCR was performed using the Perkin Elmer GeneAmp XL PCR Kit.  A manual hot start PCR reaction was 
prepared with 12 µl of 3.3X XL Buffer II, 8 µl 2.5mM dNTP, 4 µl each of 20 µM primers (sense and 
antisense), and 4 µl of Mg(OAc)2 25mM in a reaction volume of 40 µl, and heated to 94◦C.  When the 
reaction was at temperature, the following were then added: 18 µl 3.3X XL Buffer II, 1 µl rTth polymerase, 
1µl cDNA template, and 40 µl dH20.  The reaction was covered with mineral oil and allowed to cycle as 
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above.   The annealing temperature used (56◦C) was calculated as a function of the % GC of the bases that 
actually anneal to the template and the number of bases that anneal to the template. 
 
 
Figure 9: Diagram of Truncated Gene Fragments 
 
Cloning of truncated gene fragments 
 
Once PCR products were amplified, 3’ single A overhang was added by the following method.  
2.5 units of Taq polymerase was added to the PCR reaction and incubated at 72˚C for 10 minutes.  Then, 
the DNA was phenol-chloroform extracted and precipitated with 3M sodium acetate and 100% ethanol.  
DNA was pelleted by centrifugation, and washed with 70% ethanol and allowed to air dry.  It was then 
resuspended in water or Tris-Cl (pH 8.0). The entire reaction was gel electrophoresed and gel purified 
using QIAGEN QIAquick.  TOPO TA Cloning Kit (Invitrogen) was used to clone the product by the 
following method.  Five nanograms of gel purified product was added to 1 µl plasmid pCR-2.1.  Then it 
was incubated for 5 minutes at room temperature.  One microliter of 6X Cloning Stop solution was added, 
mixed and kept on ice.  Transformation into chemically competent TOP 10 cells was by the following 
method.  Two microliters of cloning reaction was added to one vial of competent cells, thawed and put on 
ice.  Cells were mixed gently and incubated on ice for 30 minutes.  The cells were then heat shocked at 
42˚C for 30 seconds and 250 µl SOC medium was added.  They were then shaken horizontally at 37˚C for 
30 minutes for ampicillin selection.  Fifty to 100 µl were plated on prewarmed Luria Broth (LB) Agar with 
ampicillin (50 µg/ml) plates and incubated at 37˚C overnight.    Ten clones were picked and grown up 
overnight in 3 mL LB medium with ampicillin (50 mg/ml) (LBA) and a patch plate was prepared.  Plasmid 
DNA was miniprepped with QIAGEN QIAprep Spin prep.  Five hundred microliters was saved for a 50% 
glycerol stock.  Clones were screened by Eco RI digestion.   
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Cloning of the full-length Dengue 1 Hawaii NS3 gene 
 
Cloning of the full-length gene was accomplished by fusing the 5’ half (“884”) and the 3’ half 
(“1116”) using a unique restriction enzyme site (BsmBI) in the overlap region of these two fragments.  See 
Figure 9.  The 884 clone and the 1116 clone (in pCR2.1 plasmid) were digested with Sal1 and BsmBI. 
Digestion reactions were gel electrophoresed on 0.7% or 2% TBE gels. The 600 bp fragment released from 
the 884 digest and the 5kb fragment from the 1116 digest were excised and gel purified with QIAGEN 
QIAquick. Epicentre Fast-Link Ligation Kit was used to anneal and ligate cohesive ends using 2 µl of the 
5kb fragment and 4 µl of the 600bp fragment.  The ligated plasmid was then transformed into TOP10 
chemically competent cells as above.  Ten clones were picked and grown in 3 ml LBA medium.  Plasmid 
DNA was minipreped and clones were screened by EcoRI digestion to release the full length (1.8kb) band. 
Once clones with full-length insert have been isolated, they were digested with Sal1 and HindIII as was the 
plasmid pMJ601.  Digests were electrophoresed on a 0.7% gel, isolated and gel purified with Qiaquick Gel 
purification kit (pMJ601at 7kb and NS3 at 1.8kb).  The Epicenter Fast-Link kit was used to ligate cohesive 
ends using 2 µl plasmid and 4 µl insert. The ligated plasmid was then transformed into TOP10 chemically 
competent cells as above.  Ten clones were picked and grown in 3 ml LBA medium.  Plasmid DNA was 
minipreped and clones were screened by Sal1/Hind III digestion to release the full length (1.8kb) band.   
Cultures of clones containing full-length gene were scaled up by a 1/500 dilution of overnight culture into 
50 ml LBA.  The cultures were grown overnight, shaking, at 37˚C.  Forty mililiters of the culture was 
maxiprepped and the DNA was resuspended in 200 µl Tris-Cl overnight.  Concentration was determined by 
spectrophotometer analysis.  One microgram of plasmid in less than 150 µl buffer was used for transfection 
into Vaccinia Virus. 
 
Sequencing of Dengue Type I NS3 Hawaii 
 
The NS3 gene was sequenced using the truncated gene fragments 884 and 1116 cloned into the 
TA cloning vector pCR2.1.  The TA cloning vector contains a M13 reverse primer site upstream of the 
cloning site, and a T7 primer downstream of the cloning site.  Sequencing primers were designed to 
encompass the entire NS3 gene.  Note that these primers were designed based on the sequence of Dengue 
Type 1 Singapore (Fu et al., 1992). 
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Recombinant Vaccinia Virus Construction 
 
A 25 cm2 flask was seeded with 106 CV-1 cells in MEM with penicillin, streptomycin and L-
glutamine (complete) with 10% FBS and was grown to 50-80% confluency (overnight) at 37˚C, with 5% 
CO2.  A vial of wild-type Vaccinia virus (wt VV) was thawed and 30 µl wt VV was mixed with 30 ul 
trypsin, vortexed and incubated for 30 minutes in a 37˚C water bath.  It was vortexed every 10 minutes and 
sonicated 2X for 30 seconds.  Twenty microliters of the solution was added to 9.28 ml MEM with 2.5% 
Bromodeoxyuridine (BrdU).  The media was aspirated off CV-1 cell layers and the cells were inoculated 
with 1 ml of wt VV solution.  The cells were incubated for 2 hours at 37˚C with 5% CO2.   One microgram 
of recombinant plasmid was diluted with 150 µl serum-free, antibiotic free MEM.  QIAGEN Superfect 
Protocol was used for transient transfection of adherent cells, as follows.  Thirty microliters of Superfect 
was added to the DNA solution and the tube was vortexed for 10 seconds and incubated at room 
temperature for 5-10 minutes.  Medium was aspirated from CV-1 cells and they were then washed with 4 
ml PBS.  One ml of 10%FBS MEM complete was added to the transfection solution and the transferred to 
the flask of cells.  The flask was incubated for 2-3 hours at 37˚C with 5% CO2.  After incubation, media 
was aspirated and cells were washed with 4mL PBS. 5 mL of fresh growth medium (10%FBS MEM 
complete) was added to the flask and it was incubated for 24 hours. 
 
Transfected cells were harvested by scraping cells from flask and they were transferred to a 15 ml tube.  
The tube was centrifuged at 2500 rpm for 5 minutes at 4˚C.   The media was aspirated off and the cell pellet 
was resuspended in 0.5 ml MEM 0.5% BrdU.  The cells were then freeze-thawed 3X in ethanol/dry ice to 
lyse cells.  The lysed cells were stored at –70˚C.  HuTK-143B cells were prepared from a continuous 
culture by seeding 5 X 105 cells/well in a 6-well plate.  Growth medium was complete MEM 10%FBS 
0.5%BrdU.   Two plates per plasmid were prepared.  And were grown at 37˚C with 5%CO2 overnight.  The 
CV-1 cell lysate was thawed and  210 µl of lysate and 210 µl trypsin were mixed and incubated for 30 
minutes in a 37˚C water bath.  The tubes were vortexed every 10 minutes and sonicated 2X for 30 seconds.  
Dilutions at 10-1, 10-2 and 10-3 were prepared.  Medium was aspirated from the HuTK-143B cells and 1 mL 
of the appropriate dilution was added.  The plates were incubated for 2 hours at 37˚C with 5% CO2, and 
were shaken occassionally.  Medium was aspirated and  2 mL /well complete MEM 10% FBS 0.5% BrdU 
was added.  Plates were incubated for 2 days at 37˚C with 5% CO2. For the plaque agarose overlay, 2% 
Low Melt agarose was melted and incubated until 45˚C.  All reagents were warmed to 45˚C.  The recipe for 
the agarose overlay is shown in Table 7 (enough for 12 wells). 
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Table 7: Agarose Overlay Mixture 
 
Reagent Volume 
2% LMP agarose 20mL 
Basal Eagle Media 20mL 
Neutral Red 600ul 
X-Gal (4%) 330ul 
BrdU (5mg/mL) 200ul 
 
Medium was aspirated from infected HuTK-143B cells.   Three ml of the agarose mixture was dripped 
slowly into each well.  Agarose was allowed to set up at room temperature for 20 minutes and the plates 
were then incubated at 37˚C with 5% CO2 overnight.   Recombinant Vaccinia Virus plaques appeared dark 
blue.  2-3 plaques were picked by inserting a Pasteur pipette into each plaque, scraping gently and taking 
up agarose plug.  Plug was then placed in a cryovial and the picking was repeated 2X-3X per plaque.   0.5 
mL complete MEM 0.5% BrdU was added to each vial.  It was then vortexed, freeze/thawed as above 3X, 
and sonicated and freeze/thawed an additional cycle. Plaque Purification in HUTK-143B cells was repeated 
2 more times.    
 
Amplification and Titeration of Recombinant Virus 
 
HuTK-143B cells were prepared in a 12-well plate and grown to confluency.  250 µl of sonicated 
plaque isolate was added to the monolayer and incubated for 2 hours at 37˚C with 5%CO2, as was hand-
rocked every 15 minutes.  Medium was aspirated and 1 ml complete MEM 10% FBS with BrdU was 
added.  Plated were incubated for 2 days until cell rounding was visible.  HuTK-143B cells were prepared 
in a 25cm2 flask and grown to near confluency.  One half of the medium was aspirated from each well in 
12-well plate.  With cell scraper, monolayer was dislodged and transferred to a cryocentrifuge tube.  Cells 
were centrifuged for 30 seconds at maximum speed and the supernatant was aspirated.  Cell pellet was 
resuspended in 0.5 ml complete MEM 2.5%FBS with BrdU.  Cells were freeze-thawed in an ethanol/dry 
ice bath 3 times. 250 µl of this lysate was diluted in 750 µl of complete MEM 2.5%FBS with BrdU.  The 
entire mixture was added to the confluent monolayer in the 25cm2 flask.  The flask was incubated for 1 
hour at 37˚C with 5% CO2.  4ml complete MEM 2.5%FBS with BrdU was overlaid and the flask was 
incubated for 2 days at 37˚C with 5% CO2.  Cells were scraped and transferred to a 15 ml conical tube.  
The tube was centrifuged for 5 minutes at 2500 rpm at 4˚C.  The cell pellet was resuspended in 0.5mL 
complete MEM 2.5%FBS with BrdU, freeze-thawed 3 times, and sonicated 2 times.  One day previously,  
5 x 107 cells in 25ml compete MEM 10%FBS were placed in a 175 cm2 flask and were incubated at 37˚C 
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with 5% CO2.  On day of infection, medium was aspirated from cells, and 250 µl lysate and 1.75 ml 
complete MEM 2.5% FBS were added to the cell layer.  The cells were incubated for 1 hour at 37˚C with 
5% CO2 and the flask was hand-rocked every 15 minutes.   25 ml complete MEM 2.5% FBS was overlaid 
on the cells and they were incubated for 3 days at 37˚C with 5% CO2. Cells were then detached by scraping 
and were transferred to a centrifuge tube and centrifuged for 5 minutes at 2500rpm at 4˚C. The medium 
was aspirated and cell pellet was resuspended in 2ml of complete MEM 2.5% FBS and was then freeze-
thawed 3 times and sonicated.  0.5 ml aliquots were prepared and stored at  –70˚C.   
Titration: 
  One 6-well plate of HuTK-143B cells was grown to near confluency for each virus to be titered.  
30 µl of previously prepared lysate and 30 µl trypsin were mixed and incubated for 30 minutes in a 37˚C 
water bath.  Dilutions 10-2 through 10-8 were made.   1 ml of dilutions 10-6, 10-7, and 10-8 were added to 
cells in duplicate wells of the 6-well plate.  The plate was incubated for 2 hours at 37˚C with 5% CO2 and 
was hand-rocked every 30 minutes.  2 ml per well of complete MEM 10% FBS was overlaid.  The plate 
was incubated for 2 days at 37˚C with 5% CO2. Medium was then aspirated and  0.5 ml of 0.2% Crystal 
violet was added to each well.  The plate was incubated at room temperature for 5 minutes.  Dye was 
aspiated and the wells were allowed to air dry.  Plaques were counted and multiplied by dilution factors, 
taking into account initial dilution with trypsin. 
 
 
Short-term Pulse Labeling of Expressed Proteins with 35S Methionine 
 
106 CV-1 cells were seeded in a 25 cm2 flask and were allowed to reattach for 2 hours.  Equal 
volumes of recombinant vaccinia virus and 0.25% trypsin were mixed and incubated at 37˚C for 30 
minutes.  Growth medium was added and 1 ml of this virus solution was added to the cell monolayer.  The 
flask was incubated for 1 hour at 37˚C with 5% CO2.  Cells were then overlaid with 4 ml MEM 10% FBS 
and incubated for 24 or 48 hours.  Media was aspirated from the flask and replaced with 0.5 ml methionine 
free MEM.  The flask was incubated for 20 minutes at 37˚C with 5% CO2.  50 µCi of 35S Methionine was 
added per flask and the flask was incubated for 30 minutes at 37˚C.  Media was removed and 2 ml ice-cold 
PBS was added.  Cells were then scraped and transferred to an eppendorf tube.  The cells were centrifuged 
at 13,000 rpm for 1 minute.  Media was aspirated and discarded.  The cell pellet was resuspended in 100 µl 
cell lysis buffer.  The tube was vortexed, incubated on ice for 5 minutes, and centrifuged at 13,000 rpm at 
4˚C for 5 minutes.  Supernatant was transferred to a new tube and stored at –20C until sample analyzation 
on SDS- PAGE gel.  An 8% SDS- Discontinuous (Laemmli) protein gel was prepared.  Cell lysate sample 
was prepared by mixing 25 µl lysate with 25 µl 2X gel loading buffer (1M DTT) and was heated at 95˚C 
for 5 minutes before loading onto gel.  The gel was run at 200-220 volts for about 2 hours.  Gel was fixed 
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in freshly prepared glacial acetic acid:methanol:water 10:20:70 with 1/100 of glycerol for 20-30 minutes. 
The gel was dried on gel dryer at less than 80˚C and analyzed by phosphorimaging. 
 
Generation of bulk culture cytotoxic T-cells 
 
Effector cells were prepared by rapidly thawing frozen PBMC from donor FS (FS PBMC).  Cells 
were washed with 5ml RPMI 10%FBS and centrifuged at 1500 rpm 2 times.  Cells were diluted to 2X106 
in a volume of 750 µl (per well) RPMI with HEPES, 10% Human AB serum, penicillin, streptomycin, and 
L-glutamine and placed in a 48-well plate.  250 µl live dengue 1 Hawaii virus was added per well, at no 
less than 107 PFU/ml.  Cells were incubated for 7 days at 37˚C with 5% CO2.   
 
Cytotoxicity Assay 
 
Target cells were prepared from BLCL from donor FS (FS BLCL).  2 to 5 x105of these cells were 
placed in a 15 conical tube and 5ml RPMI 10%FCS was added,  spun at 1500 rpm for 5 minutes, and the 
supernatant was aspirated.  To cell pellet, recombinant Vaccinia construct was added at a MOI of 5-10.  
The cell pellet was vortexed and incubated at 37˚C for 1 to 1.5 hours and was vortexed every 15 minutes.  
The tube was centrifuged and the supernatant was aspirated.  The cell pellet was resuspend in 1 ml RPMI 
20% FCS and was incubated at 37˚C with 5%CO2 overnight.  On the day of the assay, 1-2 X 105 cells were 
removed to a 15 ml conical tube. Effector to Target (E/T) Ratio was set at 37.5: and 75:1.  Cells were 
washed and the supernatants were aspirated.  25mCi of 51Cr in a 1:10 dilution with RPMI medium with 
10% FBS was added to each cell pellet.  Cells were incubated at 37˚C for 1 hour and were vortexed every 
15 minutes.  Cells were washed 2X.  1 ml of medium was added to each cell pellet, vortexed, and 50 µl was 
removed for a cell count.  4 ml of medium was added to the remaining cells and washed.    Cell dilutions 
were determined and cells were resuspended to the appropriate cell concentrations.  0.1 ml of targets was 
added to a 96-well U bottom plate.  For minimum release, 0.1 ml of growth medium was added to 6 wells 
and for maximum release 0.1 ml RENEX 1:20 dilution was added to 6 wells.  A minimum and maximum 
release was prepared for each target used.  Effectors were prepared by pooling like wells of effectors.  5 ml 
medium was added and the ells were washed.  The supernatant was aspirated and effectors were 
resuspended in 1-2 ml media.  Cell concentration was determined.  0.1 ml of effectors was added to the 
wells with targets The plate was incubated at 37˚C with 5% CO2 for 4 hours.  The plate was carefully 
removed from the incubator.  Supernatants were harvested with the Skatron Harvesting Systems.  A  
gamma counter was used to count radioactivity.   Specific lysis was determine by the formula: 
(experimental cpm-minimum cpm)/(maximum cpm-minimum cpm) X 100.   
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T-cell Cloning by Limiting Dilution 
 
Bulk culture FS T-cells were diluted to 3,1, and 0.3 cells per well with 105 gamma-irradiated 
PBMC feeders in a total volume of 100 µl.  One 96-well U-bottom plate was prepared per dilution.  Cells 
were incubated in AIM-V media supplemented with 20% FBS, 50 units/ml rIL-2, and 1/1000 of 12F6, an 
anti-CD3 monoclonal antibody for 7 days at 37˚C in 5% CO2.  On the seventh day, 100 µl AIM-V 20% 
FBC with 100 units/ml rIL-2 per well was added.   ½ of the media was changed every 3 days 
supplementing with 50 units/ml rIL-2.  Cell were restimulated with anti-CD3 mAb and gamma-irradiated 
PBMC every two weeks.  After about 1 month, clones that were growing well (large cell button) were 
transferred to a fresh 96-well plate.  Clones that are growing well were screened by CTL using 50 µl of 
each effector with 2X103 targets per well.   Remaining cells were saved and only those that showed 
vD1vNS3 specificity were restimulated.  These clones were transferred to a 48-well plate and were allowed 
to grow for 1 week.  They were then retested by CTL. 
 
CTL preparation of previously established T-cell clones 
 
T-cell clones were removed from liquid nitrogen storage and were quickly thawed in a 37˚C water 
bath.  They were quickly transferred to 5ml of RPMI 10% FBS and were spun at 1500 rpm for 5 minutes.  
The media was aspirated. Gamma-irradiated feeders were resuspended in AIM-V with 20% FBS, 50 
units/ml rIL-2 and 1/1000 12F6 mAb to about 2.7 X 106 cells/ml.  Clone cell pellets were then resuspended 
in 1 ml of feeders and were then transferred to one well of a 48-well plate.  They were incubated at 37˚C 
with 5% CO2 for 7 days.  Cells were restimulated with anti-CD3 mAb and irradiated allogenic PBMC 
every two weeks. 
 
Separation of PBMC from whole blood for use as Gamma Irradiated Feeders 
 
Whole blood was diluted with an equal volume of serum free RPMI.  30 ml of the diluted blood 
was layered slowly over 15 ml Ficoll-Hypaque in a 50ml centrifuge tube.  The tube was centrifuged at 1500 
rpm for 35 minutes with no brake.  The clear interface containing the PBMC was removed and pooled with 
another interface in a 50 ml tube.  Serum free media was added to a final volume of 50 ml and then was 
spun at 1500 rpm for 5 minutes.  The supernatant was removed and 10 ml serum free media was added to 
the pellets and vortexed. Pellets were pooled in one 50 ml tube and were irradiated for 40 minutes at 3000 
to 3500 rads.   
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Precursor Frequency Assay 
 
PBMC were quick-thawed and washed 2X in 5ml RPMI 10% FBS at 1500 rpm for 5 minutes 
media was aspirated. Cell pellet was resupended in growth medium and cells were counted.  2X107 PBMC 
were irradiated.  In two 96-well plates, prepare the following concentrations of non-irradiated PBMC in 24 
replicate wells per concentration.: 2X106cells/ml, 1X106cells/ml, 6X105cells/ml, 4X105 cells/ml, 2X105 
cells/ml, 1X105 cells/ml, 5X104 cells/ml, 0 cells/ml.  0.1 ml was added to each well.  0.1 ml of 1X106 
cells/ml gamma irradiated PBMC was added to all wells except 2X106cells/ml. 0.02 ml Dengue type 1 
Hawaii virus was added to each well and the plates were incubated for 9-10 days at 37˚C with 5% CO2.  On 
the day before the CTL, targets of autologous BLCL infected with vD1vNS3, vD3VN3, or Vac D (wt 
vaccinia) were prepared. 0.05ml effectors were tested with 2X104 targets/ml with appropriate minimum and 
maximum releases.   Negative wells were defined as having less than 10% specific lysis for each target. 
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RESULTS - PART 2 
 
Purpose of Part 2 
 
 The purpose of the second half of this thesis was to construct, evaluate, and use a vaccinia virus 
expressing the dengue virus serotype 1 NS3 protein in dengue virus specific cytotoxicity assays. 
 
 
Cloning of Dengue 1 NS3 gene into Vaccinia Transfer Vector 
 
  
The Dengue 1 NS3 gene is 1.8 kb in length.  cDNA was amplified by RT-PCR from RNA isolated 
from the dengue 1 Hawaii virus.  PCR was used to amplify the gene from the cDNA. The full-length gene 
product was divided into two segments by PCR and each fragment was cloned into the pCR2.1 vector 
(Invitrogen). The PCR incorporated two restriction enzyme sites into each gene segment.  A Sal1 site was 
included at the 5 ' end of the 5' gene segment, and a HindIII site was added at the 3' end of the 3' gene 
segment.  In addition a start codon was included at the 5' end of the PCR product.  
Using a unique restriction enzyme site of BsmBI in the overlap region of the two gene segments, 
the whole gene product was fused into the pCR2.1 plasmid. Figure 10 shows the full-length product of 1.8 
kb that was cloned into pCR2.1 (4kb) and then released from the vector by the EcoRI enzyme for analysis.  
 
Figure 10: Verification of Cloning of the Dengue 1 NS3 gene.  The NS3 gene (1.8kb) was 
released from the plasmid PCR2.1 (4kb) using EcoRI.  
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Recombinant Vaccinia Virus Isolation 
 
Once fused into pCR2.1, the NS3 gene was released with Sal1 and HindIII and ligated into the 7kb 
vaccinia transfer vector pMJ601.  Figure 11 shows the verification of this cloning.  This plasmid, created 
by Davison and Moss 1990, has a synthetic late promoter and contains the Lac Z gene and TK- (thymidine 
kinase) gene under the control of a vaccinia virus promoter.  These genes are used for selection of 
recombinant vaccinia from wild type vaccinia virus in the screening process. TK- phenotype cells were 
transfected with the pMJ601 gene construct and infected with wild type vaccinia.  Homologous 
recombination between the TK gene of the plasmid and the vaccinia genome form recombinant vaccinia 
viruses containing the gene of interest.  These were then screened out using X-gal, which in the presence of 
the Lac Z gene gives recombinant plaques a blue color, as shown in Figure 12.  In addition, the presence of 
5-bromodeoxyuridine (BrdU) kills any wild type virus expressing the TK protein because the TK protein 
phosphorylates BrdU and it is incorporated into DNA with a lethal effect.  Recombinant viruses were 
screened 3 times by agarose overlay plaquing, and were then tested for expression of the protein of interest. 
 
Figure 11:  pMJ601 Vaccinia Transfer Vector (7kb) and NS3 gene (1.8kb). They were 
digested with HindIII and Sal1 and ligated together. 
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Figure 12: Virus Plaque selection by X-gal. Dark spots indicate a functional beta-
galactosidase gene of the recombinant vaccinia viruses. 
 
 
Dengue 1 Hawaii Sequence Analysis 
 
 The full-length cDNA sequence of DEN1 Singapore strain S275/90 has been described previously 
(Fu et al, 1992).  DEN1 Hawaii has not been fully sequenced, but sequence comparison between the 
Singapore and the West Pacific strain West Pac 74 (Puri et al., 1998) shows that the NS3 gene of these two 
dengue type 1 strains are 94% homologous, lending validity to the assumption that the Hawaii strain will be 
very similar to the Singapore strain.  A portion of the sequence has been published by Chow, Seah,.and 
Chan, (1994) that comprises 426 nucleotides of the viral sequence.  Using clones of the 5’ and 3’ segments 
of the Dengue 1 Hawaii NS3 gene, the complete sequence was determined by ABI sequencing at the 
Nucleic Acid Facility of the University of Massachusetts Medical School.  This sequence is shown in 
Figure 13 and is aligned with the reference sequence Dengue 1 Singapore. A single dot indicates nucleotide 
identity.  The Hawaii sequence was found to be 95% homologous to the Singapore sequence at the 
nucleotide level.  The translation of the Hawaii gene is shown in Figure 14.  It is again shown aligned with 
the translation of the Singapore NS3 gene.  The Hawaii protein is 98% homologous to the Singapore 
protein, with 15 amino acid differences within the 619 amino acid protein.   
 
1 tctggagtgttatgggacacacctagccctccagaagtggaaagagcagt 50
1 .................................................. 50
51 ccttgatgatggtatctatagaattatgcagagaggactgttgggcaggt 100
51 .........................c....a................... 100
101 cccaagtaggagtgggagttttccaagacggcgtgttccacacaatgtgg 150
101 ....g........a..............a..................... 150
151 cacgtcaccaggggagctgtccttatgtaccaagggaagaggctggaacc 200
151 ..t....................c.....t....a............... 200
201 aagctgggccagtgtcaaaaaagacttgatctcatatggaggaggttgga 250
201 g..t.............................................. 250
251 ggtttcaaggatcctggaacacgggagaagaagtgcaggtgattgctgtt 300
251 .................................................. 300
301 gaaccaggaaaaaaccccaaaaatgtacagacagcgccgggtaccttcaa 350
301 .....g.................c.................c........ 350
351 gacccctgaaggtgaagttggagctattgccctagattttaaacccggca 400
351 ............c...........c..a...................... 400
401 catctggatctcccatcgtgaacagagaaggaaaaatagtaggtctttat 450
401 ................t...........g..................... 450
451 ggaaatggagtagtgacaacaagtggaacctacgtcagtgccatagccca 500
451 ...........g...................................t.. 500
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501 agccaaagcatcacaagaagggcccctaccagagattgaggacgaggtgt 550
501 ...t....................t......................... 550
551 ttaggaaaagaaacttaacaataatggacctacatccaggatcggggaaa 600
551 .................................................. 600
601 acaagaagatatcttccagccatagtccgtgaggccataagaaggaacgt 650
601 ...................................t....a......gc. 650
651 gcgcacactaattttggctcccacaagggttgtcgcttccgaaatggcag 700
651 ...t..g.....c..............a...........t.......... 700
701 aggcgctcaagggaatgccaataaggtaccaaacaacagcagtgaagagt 750
701 ............................t..g.................. 750
751 gaacacacaggaaaagagatagttgacctcatgtgtcacgccactttcac 800
751 .............gg..............t.....c..t........... 800
801 catgcgtctcctgtctcccgtgagagttcccaattacaacatgattatca 850
801 .............................................c.... 850
851 tggatgaagcacattttaccgatccagccagcatagcgcgcagagggtac 900
851 ................c.....................gc.......... 900
901 atctcaacccgagtgggcatgggtgaagcagctgcgatcttcatgacagc 950
901 ...........g...................................... 950
951 cactcccccaggatcggtggaggcctttccacagagcaatgcagttatcc 1000
951 .................................................. 1000
1001 aagatgaggaaagagacattcctgagagatcatggaactcaggctatgag 1050
1001 .................................................c 1050
1051 tggatcactgacttcccaggtaaaacagtctggtttgttccaagcatcaa 1100
1051 ...........t...................................t.. 1100
1101 atcaggaaatgacattgccaactgcttaagaaagaatgggaaacgggtga 1150
1101 ........................t......................... 1150
1151 ttcaattgagcaggaaaacctttgatacagagtaccaaaaaacaaaaaac 1200
1151 .c...........a..............t........g...........t 1200
1201 aacgactgggactatgtcgtcacaacagatatctccgaaatgggagcaaa 1250
1201 ..t..........................c..t..........a...... 1250
1251 cttccgagccgacagggtgatagacccaagacggtgtctgaaaccggtaa 1300
1251 ..................a..................t............ 1300
1301 tactaaaagatggtccagagcgcgtcattctagccggaccgatgccagtg 1350
1301 ......................t........................... 1350
1351 actgtggccagtgctgcccagaggagaggaagaattggaaggaaccaaaa 1400
1351 ..............c................................... 1400
1401 caaagaaggtgatcagtacgtttacatgggacagcctttaaataatgatg 1450
1401 t..g...............a......................c..c.... 1450
1451 aggatcacgctcattggacagaagcaaaaatgctccttgacaatataaac 1500
1451 ...........................................c...... 1500
1501 acaccagaagggatcatcccagccctctttgagccagagagagaaaagag 1550
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1501 ..............t....................g.......g...a.. 1550
1551 tgcagcaatagacggggagtacagactgcggggagaagcaagaaaaacgt 1600
1551 ..................a..............t........g....... 1600
1601 ttgtggagctcatgagaagaggagatctacctgtctggctatcctacaaa 1650
1601 .c................................................ 1650
1651 gttgcctcagaaggcttccagtactctgacagaagatggtgctttgacgg 1700
1651 ..................................ag...........t.. 1700
1701 ggaaaggaacaaccaggtgttggaggagaacatggacgtggagatgtgga 1750
1701 ...................c.........................c.... 1750
1751 caaaagaaggagaacgaaagaaactacgaccccgctggctggatgccaga 1800
1751 ..............a............................c...... 1800
1801 acatactcagacccactggccctgcgcgagtttaaagagtttgcagcagg 1850
1801 ........t.......a...t............................. 1850
1851 aagaag 1856
1851 ...... 1856
 
Figure 13:  Alignment of the NS3 genes of Dengue 1 Singapore (top) and Dengue 1 Hawaii 
Nucleotide sequence (bottom) 
1 SGVLWDTPSPPEVERAVLDDGIYRIMQRGLLGRSQVGVGVFQDGVFHTMW 50
1 .........................L................E....... 50
51 HVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAV 100
51 ...........E...................................... 100
101 EPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLY 150
101 .................................................. 150
151 GNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRKRNLTIMDLHPGSGK 200
151 .................................................. 200
201 TRRYLPAIVREAIRRNVRTLILAPTRVVASEMAEALKGMPIRYQTTAVKS 250
201 .............K.KL................................. 250
251 EHTGKEIVDLMCHATFTMRLLSPVRVPNYNMIIMDEAHFTDPASIARRGY 300
251 ....R.........................................A... 300
301 ISTRVGMGEAAAIFMTATPPGSVEAFPQSNAVIQDEERDIPERSWNSGYE 350
301 .................................................D 350
351 WITDFPGKTVWFVPSIKSGNDIANCLRKNGKRVIQLSRKTFDTEYQKTKN 400
351 .................................................. 400
401 NDWDYVVTTDISEMGANFRADRVIDPRRCLKPVILKDGPERVILAGPMPV 450
401 ..............E................................... 450
451 TVASAAQRRGRIGRNQNKEGDQYVYMGQPLNNDEDHAHWTEAKMLLDNIN 500
451 .......................I.......................... 500
501 TPEGIIPALFEPEREKSAAIDGEYRLRGEARKTFVELMRRGDLPVWLSYK 550
501 ..............G................................... 550
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551 VASEGFQYSDRRWCFDGERNNQVLEENMDVEMWTKEGERKKLRPRWLDAR 600
551 ...........K...................I.................. 600
601 TYSDPLALREFKEFAAGR 618
601 .....Q............ 618
Figure 14:  Alignment of NS3 Amino Acid Sequences of Dengue 1 Singapore (top) and Hawaii 
(bottom).  Yellow sections indicate areas of previously mapped epitopes.  Pink indicates the amino 
acids in Dengue 1 that are different from the mapped epitopes of Dengue 2, 3, or 4.
Analysis of Recombinant Vaccinia Protein Expression by bulk CTL  
 
In order to determine if the recombinant vaccinia viruses that were isolated after three rounds of 
screening were expressing the Dengue 1 Hawaii NS3 protein, a bulk culture assay using the PBMC of the 
donor FS was employed.  The donor FS was a volunteer who was immunized with an experimental live-
attenuated dengue virus type 1  vaccine (Green et al., 1993).   The CTL assay measures % specific lysis as 
a function of the release of 51Cr from target cells lysed by antigen-specific T-cells. Autologous B cells from 
the patient were transformed by infection with Epstein-Barr virus (BLCL).  The targets were prepared by 
infecting BLCL with the recombinant vaccinia virus and the cells were then loaded with 51Cr.  The positive 
control was cells infected with a vaccinia construct expressing the Dengue 3 NS3 protein and the negative 
control was cells infected with the wild type vaccinia virus.  Effector T-cells were prepared by stimulating 
PBMC from the patient with Dengue 1 Hawaii virus for 7 days.  The Effector to Target ratios (E/T) in the 
bulk culture CTL were 75:1 and 37.5:1.  All data points were collected in triplicate, and minimum and 
maximum release data was also collected.   As shown in Table 8, at an E/T ratio of 75:1, bulk culture T-
cells recognized targets infected with VVII2A with 47.9% specificity compared to the targets expressing 
wild-type vaccinia proteins, at 18%.  At an E/T ratio of 37.5, the VVI1A construct was not recognized at a 
level significantly higher than wild-type vaccinia.  Therefore construct II2A is more likely to be expressing 
the Dengue 1 NS3 protein efficiently.  This construct will be referred to as vD1VNS3.   
 
Table 8:  Recognition of Recombinant Vaccinia Virus Constructs by Bulk Culture CTL from Donor FS 
 
ET 75:1 ET 37.5:1 
VI1A 29.9% 21.3%
VII2A 47.9% 31.1%
VD3VNS3 34.3% 26.1%
Vac D (wt) 18.1% 19.2%
Uninfected 5.2% 2.0%
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Analysis of Recombinant Vaccinia Protein Expression by Protein Gel Electrophoresis 
 
A pulse labeling experiment was performed to visualize the recombinant NS3 protein.  The protein 
is 619 amino acids and is approximately 61 kDa.  We should expect the protein to appear slightly larger 
because the cDNA of the gene did not originally contain a stop codon.  Therefore the protein will most 
likely stop at the promoter of the flanking Lac Z gene which will contain an in-frame stop codon for protein 
expression.  This may add a few thousand daltons to the molecular weight of the expressed protein.  A short 
time course experiment was performed.  Cell cultures were infected with vD1VNS3, vD3VNS3, Vac D, or 
Dengue Hawaii virus and were harvested and labeled with 35S-Methionine at 24 or 48 hours post infection.  
Figure 15 shows the autoradiograph of the protein gel.  Lane 2 shows the protein bands of cells lysed after 
24 hours of vD1VNS3 infection.  After comparison with Lane 4, the vaccinia background, it can be seen 
that there are two band differences between these lanes.  The first is a band at about 100 kDa that is in the 
wild type vaccinia lane but not present in the recombinant construct cell lysates.  This could be a part of the 
Thymidine Kinase protein  that was lost upon homologous recombination.  The second, more significant, 
difference is a band in the vD1VNS3 lane at about 70 kDa (see arrow).  It can be hypothesized that this 
band is the dengue NS3 protein.  This data, along with the bulk culture CTL results, indicate that the 
vD1VNS3 construct is expressing the dengue NS3 protein.  A Western blot with dengue antibody would 
confirm this result.  The protein gel also shows that by 48 hours of vaccinia infection, protein expression 
was much lower than at 24 hours.  
Figure 15:  Polyacrylamide Gel Electrophoresis of 35S-Met labeled Cell Lysates of 
recombinant vaccinia virus infected cells. 
 
Use of previously isolated clones to test vD1VNS3 expression 
 
Our lab has isolated many T-cell clones that demonstrate cross-reactivity to Dengue 2,3, and 4 NS3 
proteins,but until this point none have been tested for Dengue 1 NS3 specificity using authentic NS3 
protein.  These T-cell lines were predominantly isolated from a Dengue 3 candidate vaccine recipient (JK) 
and their antigenic epitopes have been mapped.  As shown in Figure 16, the epitope recoginized by clone 
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JK34 shares 100% identity with the Dengue 1 Hawaii amino acid sequence at this epitope. The epitopes 
recognized by clones JK13 and JK 44 share 9/10 amino acids with the Hawaii sequence.  The antigenic 
epitope of clone JK 43 is 78% homologous to the Dengue 1 Hawaii sequence.  The epitope recognized by 
clone CB6.17 (isolated from a Dengue 4 infected individual, CB) shares 8/9 amino acids with the Hawaii 
sequence. 
 
 
Clone   Epitope sequence from Serotype Epitope Similarity 
 JK 34   Dengue 3   EIVDLMCHAT 
  Hawaii  Dengue 1   ..........
JK 44   Dengue 3   RKYLPAIVRE
  Hawaii  Dengue 1   .R........
JK 43   Dengue  3   VIGLYGNGV 
  Hawaii  Dengue 1   IV.......     
 JK 13   Dengue 3   WITDFVGKTVW
Hawaii  Dengue 1   .....P.....
CB 6.17   Dengue 4   TPEGIIPTL
Dengue 3   .......A.
  Hawaii  Dengue 1   .......A. 
Figure 16: Comparison of T-cell epitopes of D3 or D4 NS3 proteins with Dengue 1 Hawaii Sequence. 
Note: A single dot indicates identical amino acid in that position. 
It would be expected that the more similar the Hawaii sequence is to the antigenic epitope of the T-cell 
clone, the more lysis will be observed.   These clones were tested against autologous BLCL infected with 
recombinant vaccinia viruses expressing the D1V and D3V NS3 proteins, and the wild type vaccinia virus 
("Vac D").  The % specific lysis is shown in Table 9.  
 
Table 9: Recognition of recombinant vaccinia viruses by dengue virus-specific CTL clones.  Vac D is the 
wild type vaccinia virus.  ET ratios for all experiments were 10:1.  ND indicates experiments not done.  
Background levels were particularly high for experiment 1. 
 
Clone V V % Specific 51 Cr Release by: 
Exp. 1 Exp. 2 
JK 34 D1NS3 14 -6 
 D3NS3 15 57 
 Vac D -31 4 
JK 43 D1NS3 77 83 
 D3NS3 63 98 
 Vac D -38 11 
JK 44 D1NS3 66 76 
 D3NS3 20 97 
 Vac D -33 4 
JK 13 D1NS3 21 -4 
 D3NS3 27 22 
 Vac D -28 5 
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CB 6.17 D1NS3 -1 0 
D4NS3 ND 71 
Vac D 24 1 
 
 JK 34 unexpectedly did not recognized the dengue 1 NS3 construct.  The epitope of dengue 1 is 
exactly the same as the dengue 3 construct that was mapped for the clone.  The clone did show recognition 
of the dengue 3 construct.  Okamoto et al. (1998) reported that JK 34 is cross reactive for dengue 1 when 
stimulated with dengue virus antigen.  The vaccinia virus backbone may be interfering with the eventual 
presentation of the epitope to this clone.  It is unclear how this might occur 
 JK 43 and 44 recognize the dengue 1 construct even though the mapped epitopes for these two 
clones are slightly different than the sequence of the dengue 1 Hawaii protein.  The amino acid differences 
are not significant enough to alter presentation and recognition of the Hawaii epitopes, as is demonstrated 
in Table 9 in the second experiment.  JK 43 had a specific lysis of dengue 1 NS3 targets of 83% and dengue 
3 NS3 targets of 98%.  JK 44 had similarly high recognition at 76% and 97 % respectively.  JK 44 dengue 
1 protein has a lysine substituted for the arginine in the dengue 3 mapped epitope, as shown in Table 9.  
These two amino acids are basic. The epitope for JK 43 has a valine and an isoleucine at the first and 
second amino acid positions.  These are isoleucine and valine in the first and second spots of the dengue 1 
protein.  These are both neutral non-polar amino acids and the swapping of their positions does not seem to 
influence recognition of the epitope to a great degree. 
 JK 13 was previously determined to be a dengue 3 specific clone (Zeng et al., 1996).  Although he  
background for targets expressing dengue 3 NS3 was high for both experiments, it can be seen from 
Experiment 2 in Table 9 that JK 13 recognizes dengue3 NS3 to a higher degree than the dengue 1 protein.   
 CB6.17 was previously determined to be a dengue 4 specific clone (Livingston at al., 1995).  
Experiment 2 shows that CB6.17 recognizes the dengue 4 NS3 protein with 71% specific lysis while it does 
not recognize the dengue 1 protein.   
 These experiments show that the recombinant vaccinia virus constructed in this study is 
expressing the dengue 1 NS3 protein.  This protein can be recognized appropriately by clones that are 
reactive to the protein.  Conversely, the presence of the protein does not significantly activate T-cell clones 
that are specific for the NS3 protein of other serotypes.   
 
Attempted isolation of D1V NS3 specific T-cell Clones from FS PBMC 
 
 Limiting dilution of the FS T-cell population stimulated with Dengue 1 Hawaii virus was 
performed.  These clones were diluted to 3, 1 or 0.3 cells per well and were allowed to grow for about 1 
month.  These clones were then screened by CTL against targets infected with vD1VNS3 or VacD.  Four 
clones FS9, FS11, FS7.3 and FS8.3 were selected as possible candidates for D1V NS3 specificity.  After 
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restimulation and a short growth period, these clones were retested against targets expressing D1VNS3, 
D3VNS3,  and Vac D.  Data (not shown) indicate that these clones are not Dengue 1 NS3 specific. 
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Precursor Frequency Assay 
 
 The precursor frequency assay is a quick technique to estimate the existence and abundance of a 
specific T-cell population in the original T-cell population.   Donor FS PBMC were plated in 24 wells of a 
96-well plate in decreasing cell dilutions and were stimulated with autologous gamma-irradiated PBMC 
and dengue 1 virus.  They were allowed to incubate for 15 days until the cell buttons were sufficiently large 
for a CTL assay.   A quarter of each well was removed to a clean 96 well plate and were tested against 
autologous BLCL infected with vaccinia recombinants expressing dengue 1 or dengue 3 NS3 proteins or 
wild type vaccinia.  
 
Table 10:  Mean and Standard Deviation Values for Dengue 1 NS3 Precursor Frequency Assay 
 
Target  MEAN 24 wells Standard Deviation St. Dev * 3 Mean +3ST.D 
vD1NS3 0 cells/well 315 15 45 360 
vD3NS3 0 cells/well 272 25 76 348 
VacD 0 cells/well 345 20 60 405 
 
The mean of 24 replicate base-line wells (0cells/well) was determined, and the standard deviation was 
calculated.  The percent lysis was determined with these values.   A negative well was defined as any well 
having a percent lysis less that 10%.  Negative wells were tallied for each of the 3 experimental targets.  
The proportion of negative wells was graphed versus the number of cells per well, as shown in Figure 17. 
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 Figure 17:  Precursor Frequency of dengue 1 NS3 specific T-cells.  The equations for each line are: 
D1V [log 0.37=-6.05 x 10-6(x) -0.35]  D3V  [log 0.37 = -4.333 x 10-6 (x) + 0.0142]  Vac  [log 0.37 = 
-7.8x 10-7 (x) = 0.0333] 
 
 
The precursor frequency is calculated from the equation of the best-fit logarithmic trend line for 
each data set.  One can solve for the x value when the y value is set at 0.37.  This value was determined by 
Sharrock, Kaminski and Man (1990). When 37% of the test cultures are negative, there is an average of one 
precursor per well.  The T-cell frequency was highest for dengue 1 NS3, at 1 in 65,586 PBMC.  The 
precursor frequency of dengue 3 NS3-specific T-cells is 1 in 103,002 PBMC and for vaccinia-specific T-
cells, 1 in 596,280 PBMC.    
Once the precursor frequency was calculated, each well was assessed for specific lysis of 
D1VNS3-expressing targets.  This is calculated using the equation: (experimental cpm-minimum 
cpm)/(maximum cpm-minimum cpm)*100.  Minimum, or spontaneous, release is generated from 6 
replicate wells with targets that are treated with medium only.  Maximum release is generated from 6 
replicate wells of targets treated with RENEX, which lyses all cells.  Wells that had a significant amount of 
D1V NS3 specific lysis over D3VNS3 or VacD lysis were saved for further limiting dilution in order to 
isolate dengue 1 NS3 specific T-cell clones.   The wells that showed significant dengue 1 NS3 lysis are 
shown in Table 11 comparing dengue 1 NS3, dengue 3 NS3, and wild-type vaccinia specific lysis. 
 
Table 11: Comparison of Precursor Frequency well specific lysis.  Only wells with significant recognition 
of Dengue 1 NS3 targets are shown here. 
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Cell Cells/well D1NS3 % Lysis D3NS3  %Lysis vacD%lysis 
B1 2.00E+05 60 8 -2 
B7 2.00E+05 73 14 4 
C1 1.00E+05 108 16 0 
C5 1.00E+05 22 -4 -6 
C6 1.00E+05 74 29 9 
D2 1.00E+05 25 4 -4 
D10 1.00E+05 53 3 -9 
E1 6.00E+04 18 -12 -13 
E7 6.00E+04 74 -1 0 
E8 6.00E+04 43 -12 -3 
E9 6.00E+04 32 3 -6 
F3 6.00E+04 21 -3 -8 
F6 6.00E+04 20 -8 -13 
F9 6.00E+04 28 5 -9 
F10 6.00E+04 21 -3 -2 
F11 6.00E+04 33 0 -3 
G12 4.00E+04 26 -4 -6 
 
 
NS3 specificity of previously established FS CD4+ CD8- clones 
 
 Donor FS was the recipient of an experimental live-attenuated dengue virus serotype 1 vaccine.  
The donor was a 38-year-old white male who had never traveled outside of the US and showed no 
flavivirus antibody response before vaccination.  He received the vaccine strain DEN-1 45 AZ5 PDK 
passage 27.  Four months post immunization, peripheral blood was obtained.  This donor had a 
predominantly serotype specific T-cell response.  A precursor frequency assay showed that 80% of the T-
cell clones isolated from this donor were serotype specific while 20% were serotype 1 and 3 subcomplex 
specific, as determined by serotype antigen presentation (Green et al., 1993). 
 Several CD4+ CD8- clones have been isolated from this donor.  Clones FS 5, 7, 20, and 24 were 
determined to be dengue serotype 1 specific when stimulated with dengue virus antigen.  Clones 10 and 15 
are dengue serotype 1 and 3 subcomplex specific.  Other CD4+ clones were isolated and were shown to 
recognize the NS1-NS2a proteins expressed by a recombinant vaccinia virus (Green et al., 1997).  Until 
this point no clones have been tested for NS3 specificity because of the lack of a recombinant vaccinia 
virus expressing this protein.  This study tested clones FS 5, 7, 10, 15, 20 and 24 for dengue serotype 1 NS3 
protein specificity.  It should be noted that clones 5, 7, 10 and 20 were found to be non-reactive towards the 
NS1 or NS2a proteins.  As is shown in Table 12, the spontaneous release (min) was high for this 
experiment, causing the % lysis values to be negative.  None of the clones shown here are dengue 1 NS3 
specific. 
Table 12:  Dengue 1 and 3 NS3 Specific Lysis by FS Clones 5, 7, 10, 15, 20 and 24. 
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 D1NS3 % Lysis D3NS3 % Lysis vacD % Lysis 
FS 5 -3 -12 -13 
FS 7 -3 -4 -7 
FS 10 0 -4 -7 
FS 15 -1 -6 -10 
FS 20 -21 -5 -11 
FS 24 -1 1 -7 
Min 547 470 254.5
Max 1401.5 1493.5 708
Min/max 39 31 36
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DISCUSSION-PART 2 
 
 
 The purpose of Part 2 of this study was to construct and use a recombinant vaccinia virus 
expressing the dengue type 1 NS3 protein in immunological studies.  The vaccinia virus expression system 
has been well established for use in immunological studies.  Antigenic specificity of cytotoxic T-cells can 
be studied using recombinant vaccinia virus infected cells.  The benefits of using the vaccinia virus 
expression system include cytoplasmic transcription of the foreign gene and control of transcription by 
various vaccinia virus promoters.  When a protein needs to be expressed in the context of the major 
histocompatibility complex class 1 molecule, a compound early/late promoter may be used.   
 The dengue 1 Hawaii NS3 gene was sequenced in this study.  The Hawaii gene was shown to be 
95% homologous to the dengue type 1 Singapore strain.  The amino acid sequence of the Hawaii NS3 
protein was 98% homologous to the Singapore strain.  This sequence data confirms that the Hawaii strain is 
distinct from the other dengue type 1 strains.   From this data, we can make educated hypotheses about 
what epitopes of the protein may or may not be recognized by T-cell clones.   
 The recombinant vaccinia virus constructed in this study was shown to be expressing the dengue 
type 1  NS3 protein.  Electrophoresis of cellular proteins of cells infected with the recombinant vaccinia 
virus showed a band at the expected size of the dengue 1 NS3 protein, which is about 61 kDa.  Additional 
evidence was provided by a bulk CTL assay with the PBMC of donor FS.  The assay showed that the 
dengue 1 NS3 protein was being expressed and was recognized at a significant level by cytotoxic T-cells of 
the donor.  In addition, this assay showed that dengue 1 NS3 specific T-cells are present in the PBMC of 
this donor.    Further CTL assays using CTL clones from donors JK and CB showed that the dengue 1 NS3 
protein does not activate clones that are not primed for the epitopes of the dengue 1 Hawaii NS3 protein.   
These experiments also showed that although an epitope may vary by one or two amino acids, it may still 
be recognized by a T-cell clone.  We concluded that the recombinant vaccinia virus is properly expressing 
the dengue type 1 NS3 protein.   
 The donor FS was a volunteer experimental dengue 1 vaccine recipient.  Several studies (Green et 
al., 1993; Green et al., 1997) have investigated this donor's cytotoxic and memory T-cell specificities.  
CD4+ T-cell clones were established and using recombinant vaccinia viruses, several clones were shown to 
be dengue 1 NS1 or NS2a specific. These studies established that 80% of the CD4+ clones isolated were 
dengue 1 specific and 20% were dengue 1 and dengue 3 cross reactive.  No dengue 2 or 4 reactive clones 
were isolated.  This can be explained by the high homology shared between dengue serotypes 1 and 3.  
However none of these clones were tested for dengue 1 NS3 specificity with authentic NS3 protein.  It 
would be hypothesized that because this donor has a predominantly serotype specific T-cell response and 
because the NS3 protein is highly antigenic, there exist dengue 1 NS3 specific T-cells.  The precursor 
frequency assay conducted in this study supports this hypothesis.  Approximately 19 of the 96 wells of the 
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precursor frequency assay showed a significant percent specific lysis of dengue 1 NS3 targets over dengue 
3 NS3 targets.  These wells could, of course, contain a mix of dengue 1 specific and dengue 1 and 3 
subcomplex specific T-cells.  Isolation of dengue 1 NS3 specific T-cell clones is possible by limiting 
dilution of these positive wells. 
In the present study, several of the previously established FS CD4+ clones were examined for 
dengue 1 NS3 protein recognition using the recombinant vaccinia virus constructed in the earlier part of 
this study (Green et al., 1997)  Six FS clones were tested and none were shown to be dengue 1 NS3 
specific, although the small sample size is a factor to be taken into account.  The precursor frequency for 
dengue 1 total antigen specific T-cells was established by Green et al. (1993) to be 1 in 1,686 PBMC, while 
the precursor frequency of dengue 1 NS3 specific T-cells was calculated to be 1 in 65,586 PBMC for this 
donor.  This value is logical because the frequency of serotype specific protein specific T-cells is going o 
be much lower than just serotype specific T-cells. The values for the vaccinia specific T-cells was very low 
(1 in 596,280) because there should not be any Vaccinia specific T-cell stimulation when the T-cells are 
stimulated with Dengue 1 virus.  Although it is currently unknown how the frequency of specific T-cell 
populations and illness recovery are correlated, precursor frequency is valuable for understanding immune 
response to dengue infection, whether induced naturally or by a vaccine. 
Our laboratory has been studying dengue virus specific immune responses in order to further our 
knowledge of the role of T-lymphocytes in the pathogenesis of dengue diseases and disease recovery.  
Generally, PBMC from naturally infected or immunized individuals are examined for memory and 
cytotoxic T-cell abundance.  T-cell clones are then established in order to study the T-cell repertoire that 
each dengue serotype induces, as well as map antigenic epitopes of the viral proteins.  This gives us a better 
understanding of which proteins are the most antigenic, which then can serve as targets for vaccine 
development.   
 Until this point, studies have used vaccinia viruses expressing dengue 2, 3, and 4 NS3 proteins to 
investigate NS3 specific T-cell responses.  NS3 has been shown to be one of the most antigenic viral 
proteins (Gagnon et al., 1996;  Mathew et al., 1996).  However, a vaccinia virus expressing the dengue 
serotype 1 NS3 protein has not been available.  Without this construct, dengue NS3 studies have been 
incomplete.  As shown in this study, a recombinant vaccinia expressing the dengue 1 NS3 protein is now 
available.  Through CTL assays and protein gel electrophoresis, the current research demonstrates that the 
recombinant virus is expressing the NS3 protein in a form that can be recognized in the context of the HLA 
Class 1 molecule. 
 The development of such a vaccine has been a focus of infectious disease researchers for almost 
20 years.  Dengue diseases are a serious health problem in South America and Asian countries, where the 
mosquito species Aedes aegypti breeds.  The dengue virus exists as four distinct serotypes 1, 2, 3 and 4.  It 
has been shown that protective immunity to the serotype of the primary infection can provide life-long 
immunity but secondary infection with a heterologous serotype can cause severe illness in adults, including 
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Dengue Hemorrhagic Fever and Dengue Shock Syndrome.  This phenomenon, called antibody dependent 
enhancement, complicates vaccine development.  In addition, other flaviviruses such as Yellow Fever and 
Japanese Encephalitis cause some cross-reactive T-cell responses. It is unknown how the antibodies elicited 
by vaccines for these viruses will affect individuals that are immunized with a dengue virus vaccine. 
 The major reason that dengue virus research is ongoing is one of national security.  Because the 
dengue virus is not indigenous to the United States, U.S. citizens are dengue naïve.  A major concern when 
sending military troops overseas is the health threats they will encounter.  Dengue illnesses are a major 
threat in many countries to which we have sent troops, such as Somalia, Haiti, and the Philippines.  For 
example, during Operation Restore Hope in Somalia in 1992-1993, 43% of 96 soldiers hospitalized with a 
fever were diagnosed with Dengue Fever.  (Sharp et al, 1995).  Governmental agencies are interested in 
protecting our troops from being incapacitated by illness, including dengue diseases.  A dengue vaccine 
would be very valuable to our government.   
 Another immediate concern is that the Aedes aegypti mosquito has been found in many of our 
southern states.  As a result, the number of natively acquired dengue infections has been increasing.  In 
1997, seven cases of locally acquired dengue infection were reported in Texas (Rawlings et al., 1998).  As 
dengue epidemics occur closer to our southern borders, there is an increasing chance of an epidemic in 
states such as Texas, Louisiana, and Florida.  The northward movement of the mosquito breeding grounds 
has been hypothesized to be correlated with the global warming effect (Reiter, 1996).  
 The development of an effective vaccine is not only enhanced by immunological research.  
Molecular biology can also provide useful research tools for the investigation of dengue pathogenesis.  In 
the earlier part of this research, several genes were identified as being potentially upregulated due to 
dengue infection.  These are genes that are not commonly thought to be associated with dengue infection, 
but the fact that they may be upregulated may lead to some interesting insight into the mechanism of some 
of the symptoms of dengue diseases and help identify targets for therapeutic intervention.  Techniques such 
as PCR, gene sequencing and Differential Display can be used in a multi-focal analysis of dengue biology.    
 There are many directions in which dengue research is currently going.  Experimental vaccine 
studies are on-going, as is clinical research of indigenous secondary infection in children in Thailand.  
Future research stemming from this study include isolation of dengue type 1 NS3 specific T-cells from 
donor FS and subsequent T-cell epitope mapping.  This information would be added to the epitope data that 
already exist for the dengue virus.  Of more immediate importance is the use of the recombinant vaccinia 
virus constructed in this study.  It will be used to investigate CD4+ T-cell specificities in vaccine recipients.  
A correlation between the serotype causing infection and disease severity has yet to be shown but vaccinia 
constructs will be used to further this research and are valuable tools for labs researching dengue 
pathogenesis. 
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